US20230381102A1 - Rinse-off compositions and uses thereof for delivery of active agents - Google Patents
Rinse-off compositions and uses thereof for delivery of active agents Download PDFInfo
- Publication number
- US20230381102A1 US20230381102A1 US18/365,074 US202318365074A US2023381102A1 US 20230381102 A1 US20230381102 A1 US 20230381102A1 US 202318365074 A US202318365074 A US 202318365074A US 2023381102 A1 US2023381102 A1 US 2023381102A1
- Authority
- US
- United States
- Prior art keywords
- composition
- rinse
- agent
- active agents
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 320
- 239000013543 active substance Substances 0.000 title claims abstract description 121
- 239000004094 surface-active agent Substances 0.000 claims abstract description 59
- 210000004761 scalp Anatomy 0.000 claims abstract description 49
- 239000002904 solvent Substances 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 35
- 239000002453 shampoo Substances 0.000 claims abstract description 35
- 239000011159 matrix material Substances 0.000 claims abstract description 30
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 8
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- -1 acrylamidopropyl Chemical group 0.000 claims description 47
- 239000003921 oil Substances 0.000 claims description 42
- 235000019198 oils Nutrition 0.000 claims description 42
- 229950008396 ulobetasol propionate Drugs 0.000 claims description 41
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 37
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 26
- 239000003945 anionic surfactant Substances 0.000 claims description 25
- 229920006317 cationic polymer Polymers 0.000 claims description 24
- 238000000151 deposition Methods 0.000 claims description 23
- 230000008021 deposition Effects 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 239000002280 amphoteric surfactant Substances 0.000 claims description 14
- 125000002091 cationic group Chemical group 0.000 claims description 14
- 239000002736 nonionic surfactant Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 8
- 235000019477 peppermint oil Nutrition 0.000 claims description 8
- 229960004703 clobetasol propionate Drugs 0.000 claims description 7
- 239000003246 corticosteroid Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 6
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 5
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 5
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 5
- 229950011318 cannabidiol Drugs 0.000 claims description 5
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 5
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 4
- 244000060011 Cocos nucifera Species 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003420 antiserotonin agent Substances 0.000 claims description 4
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims description 4
- 229960002882 calcipotriol Drugs 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 229940086555 cyclomethicone Drugs 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- 206010012504 Dermatophytosis Diseases 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 229960004495 beclometasone Drugs 0.000 claims description 3
- 229960002537 betamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940098691 coco monoethanolamide Drugs 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 229960002475 halometasone Drugs 0.000 claims description 3
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229960001664 mometasone Drugs 0.000 claims description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000768 polyamine Polymers 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 3
- 229960000401 tranexamic acid Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- NBMKJKDGKREAPL-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-CXSFZGCWSA-N 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims description 2
- ZMYGOSBRLPSJNB-SOMXGXJRSA-N Amelometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O ZMYGOSBRLPSJNB-SOMXGXJRSA-N 0.000 claims description 2
- 206010002388 Angina unstable Diseases 0.000 claims description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims description 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims description 2
- 229940097420 Diuretic Drugs 0.000 claims description 2
- 229940122880 Estrogen receptor agonist Drugs 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 2
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 2
- 229940124091 Keratolytic Drugs 0.000 claims description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims description 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 229940123251 Platelet activating factor antagonist Drugs 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 2
- 206010040829 Skin discolouration Diseases 0.000 claims description 2
- 229930182558 Sterol Natural products 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 2
- 208000007814 Unstable Angina Diseases 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims description 2
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 2
- 239000000464 adrenergic agent Substances 0.000 claims description 2
- 230000001780 adrenocortical effect Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229960000552 alclometasone Drugs 0.000 claims description 2
- 229960004229 alclometasone dipropionate Drugs 0.000 claims description 2
- 239000002170 aldosterone antagonist Substances 0.000 claims description 2
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 2
- 229960003099 amcinonide Drugs 0.000 claims description 2
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims description 2
- 229950008046 amelometasone Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000001195 anabolic effect Effects 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 230000003555 analeptic effect Effects 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000001539 anorectic effect Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000058 anti acne agent Substances 0.000 claims description 2
- 230000001466 anti-adreneric effect Effects 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000003266 anti-allergic effect Effects 0.000 claims description 2
- 230000000398 anti-amebic effect Effects 0.000 claims description 2
- 230000000567 anti-anemic effect Effects 0.000 claims description 2
- 230000003257 anti-anginal effect Effects 0.000 claims description 2
- 230000002456 anti-arthritic effect Effects 0.000 claims description 2
- 230000001088 anti-asthma Effects 0.000 claims description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000002686 anti-diuretic effect Effects 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 230000003556 anti-epileptic effect Effects 0.000 claims description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims description 2
- 230000002364 anti-haemorrhagic effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000002959 anti-hypotensive effect Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002460 anti-migrenic effect Effects 0.000 claims description 2
- 230000002927 anti-mitotic effect Effects 0.000 claims description 2
- 230000001857 anti-mycotic effect Effects 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 2
- 230000001262 anti-secretory effect Effects 0.000 claims description 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 claims description 2
- 230000000767 anti-ulcer Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 229940124340 antiacne agent Drugs 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940124538 antidiuretic agent Drugs 0.000 claims description 2
- 239000003160 antidiuretic agent Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940124572 antihypotensive agent Drugs 0.000 claims description 2
- 239000002543 antimycotic Substances 0.000 claims description 2
- 239000002579 antinauseant Substances 0.000 claims description 2
- 239000003096 antiparasitic agent Substances 0.000 claims description 2
- 239000003213 antiperspirant Substances 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003200 antithyroid agent Substances 0.000 claims description 2
- 239000002830 appetite depressant Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- 229960004311 betamethasone valerate Drugs 0.000 claims description 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
- 229940125690 blood glucose regulator Drugs 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 229940065144 cannabinoids Drugs 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 230000001713 cholinergic effect Effects 0.000 claims description 2
- 229960003728 ciclesonide Drugs 0.000 claims description 2
- 229960004375 ciclopirox olamine Drugs 0.000 claims description 2
- 229960003344 climbazole Drugs 0.000 claims description 2
- 229960005465 clobetasone butyrate Drugs 0.000 claims description 2
- 239000011280 coal tar Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229950011211 cormetasone Drugs 0.000 claims description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims description 2
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229960003290 cortisone acetate Drugs 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 230000002951 depilatory effect Effects 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 229960003662 desonide Drugs 0.000 claims description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 2
- 229960002593 desoximetasone Drugs 0.000 claims description 2
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 229940005501 dopaminergic agent Drugs 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 229960003469 flumetasone Drugs 0.000 claims description 2
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229960003973 fluocortolone Drugs 0.000 claims description 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 2
- 229960002650 fluprednidene acetate Drugs 0.000 claims description 2
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 claims description 2
- 210000004211 gastric acid Anatomy 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 2
- 229940124563 hair growth stimulant Drugs 0.000 claims description 2
- 229960002383 halcinonide Drugs 0.000 claims description 2
- 230000002439 hemostatic effect Effects 0.000 claims description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960002453 hydrocortisone aceponate Drugs 0.000 claims description 2
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 claims description 2
- 229960002846 hydrocortisone probutate Drugs 0.000 claims description 2
- 229960000631 hydrocortisone valerate Drugs 0.000 claims description 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 2
- 230000003810 hyperpigmentation Effects 0.000 claims description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 208000021822 hypotensive Diseases 0.000 claims description 2
- 230000001077 hypotensive effect Effects 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229940124452 immunizing agent Drugs 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 2
- 229960005280 isotretinoin Drugs 0.000 claims description 2
- 230000001530 keratinolytic effect Effects 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 230000000510 mucolytic effect Effects 0.000 claims description 2
- 230000002911 mydriatic effect Effects 0.000 claims description 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 2
- 239000000133 nasal decongestant Substances 0.000 claims description 2
- 239000000842 neuromuscular blocking agent Substances 0.000 claims description 2
- 230000000324 neuroprotective effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229960002858 paramethasone Drugs 0.000 claims description 2
- 239000000575 pesticide Substances 0.000 claims description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims description 2
- 229940081510 piroctone olamine Drugs 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229960002794 prednicarbate Drugs 0.000 claims description 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 230000000506 psychotropic effect Effects 0.000 claims description 2
- 229960001141 pyrithione zinc Drugs 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 230000003716 rejuvenation Effects 0.000 claims description 2
- 229960001755 resorcinol Drugs 0.000 claims description 2
- 239000003229 sclerosing agent Substances 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 claims description 2
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005265 selenium sulfide Drugs 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 150000003432 sterols Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims description 2
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 229960005349 sulfur Drugs 0.000 claims description 2
- 239000011269 tar Substances 0.000 claims description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 2
- 229960002722 terbinafine Drugs 0.000 claims description 2
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims description 2
- 239000005495 thyroid hormone Substances 0.000 claims description 2
- 229940036555 thyroid hormone Drugs 0.000 claims description 2
- 230000000929 thyromimetic effect Effects 0.000 claims description 2
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 claims description 2
- 229960003114 tixocortol pivalate Drugs 0.000 claims description 2
- 229940125725 tranquilizer Drugs 0.000 claims description 2
- 239000003204 tranquilizing agent Substances 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 239000003357 wound healing promoting agent Substances 0.000 claims description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229960002255 azelaic acid Drugs 0.000 claims 1
- 229960004299 clocortolone Drugs 0.000 claims 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 5
- 239000012071 phase Substances 0.000 description 42
- 150000003839 salts Chemical class 0.000 description 30
- 229940021221 clobex Drugs 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 239000012453 solvate Substances 0.000 description 12
- 239000003755 preservative agent Substances 0.000 description 11
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 239000003906 humectant Substances 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 239000003002 pH adjusting agent Substances 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000000518 rheometry Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920000289 Polyquaternium Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940043810 zinc pyrithione Drugs 0.000 description 2
- 239000004711 α-olefin Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QVTPFMPYKMLGGK-QPZANWORSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-6,6,9-trifluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-8,11,12,14,15,16-hexahydro-7h-cyclopenta[a]phenanthren-3-one Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O QVTPFMPYKMLGGK-QPZANWORSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- RJURRZFUWSRXDY-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.CC(O)OC1=CC=CC=C1 RJURRZFUWSRXDY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960001357 clocortolone pivalate Drugs 0.000 description 1
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920013750 conditioning polymer Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- YSRSBDQINUMTIF-UHFFFAOYSA-N decane-1,2-diol Chemical compound CCCCCCCCC(O)CO YSRSBDQINUMTIF-UHFFFAOYSA-N 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000003061 homeopathic agent Substances 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XLCIFRJORZNGEV-UHFFFAOYSA-N propan-2-yl 2-[dodecanoyl(methyl)amino]acetate Chemical compound CCCCCCCCCCCC(=O)N(C)CC(=O)OC(C)C XLCIFRJORZNGEV-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229940095673 shampoo product Drugs 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- DIORMHZUUKOISG-UHFFFAOYSA-N sulfoformic acid Chemical compound OC(=O)S(O)(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present application pertains to rinse-off compositions useful, for example, for the delivery and deposition of active agents, such as active pharmaceutical ingredients (APIs), in particular hydrophobic APIs. More specifically, the application is directed to a rinse-off composition, such as a shampoo composition, comprising an oil phase and an aqueous surfactant matrix wherein one or more active agents are dissolved in the oil phase, as well as methods and uses thereof for delivering the one or more active agents to a subject.
- active agents such as active pharmaceutical ingredients (APIs)
- APIs active pharmaceutical ingredients
- hydrophobic and poorly soluble APIs in a surfactant-rich and aqueous based composition may be challenging due, for example, to the instability of such compositions and poor solubility of the API in such media.
- This problem is accentuated in personal care products such as rinse-off compositions including shampoo, where ideally the product is applied only for a short amount of time, enough to allow appropriate foaming and rinsing off, but there is a need to deposit sufficient API on the hair and skin during product application to permit diffusion of the API to the site of pharmacological action.
- API-containing rinse-off delivery system such as a shampoo
- many APIs such as corticosteroids (e.g., clobetasol propionate, halobetasol propionate) are highly hydrophobic and water-insoluble.
- U.S. Pat. No. 6,495,498 B2 discloses a shampoo composition comprising a water-soluble silicone agent, a cationic conditioning agent and a detergent for the delivery of benefit agents. However, this patent does not disclose the solubilization of active agents in an oil phase.
- U.S. Pat. No. 4,835,148 discloses a rinse-off shampoo composition targeting skin disorders of the scalp that requires insoluble particulates of API to come out of suspension upon dilution during hair wash thus depositing onto the scalp.
- This method of delivery is usually ineffective for APIs that need to permeate the skin to have therapeutic effect, since water-insoluble particulates generally do not diffuse to the site of pharmacological action nor produce pharmacological activity, and must undergo dissolution in sebum in situ before such diffusion and activity can occur.
- U.S. Pat. No. 6,183,757 B1 discloses a rinse-off antimicrobial cleansing composition comprising an antimicrobial active, an anionic surfactant and cationic polymers as deposition aids in an aqueous composition.
- this patent fails to teach solubilization of hydrophobic APIs in a water-immiscible oil phase.
- composition containing a hydrophobic API for personal care products such as shampoo for hair cleansing and other rinse-off products, that is convenient to use (e.g., short leave-on time) and allows for deposition of said API onto the skin and hair and subsequent diffusion to a site at which it exerts its pharmacological activity.
- Rinse-off compositions containing hydrophobic, water-insoluble active agents dissolved in a water-insoluble oil phase are disclosed herein for topical dermatologic use.
- Rinse-off compositions of the present application have reduced topical application time compared to current rinse-off compositions comprising water-insoluble hydrophobic active agents, e.g., those dissolved in a hydroalcoholic surfactant matrix.
- the compositions also have improved stability, active agent deposition amounts, and/or score favorably in actual in use (wear) studies on subjects.
- the present application relates to a rinse-off composition
- a rinse-off composition comprising:
- the present application relates to a method of topically administering
- one or more active agents to a subject in need thereof:
- the present application relates to a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
- the present application relates to a method of treating and or
- an active agent comprising:
- the present application relates to a method of cleansing hair, scalp, skin and/or other anatomical surface of a subject in need thereof comprising:
- the present application relates to a use of a rinse-off composition of the present application to administer one or more active agents to a subject in need thereof.
- the present application relates to a use of a rinse-off composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- the present application relates to a use of a rinse-off composition of the present application to cleanse hair, scalp, skin, and/or other anatomical surface of a subject in need thereof.
- composition(s) of the application or “composition(s) of the present application” and the like as used herein refers to a rinse-off composition comprising at least an oil phase, an aqueous surfactant matrix, and an active agent dissolved in the oil phase as described herein.
- suitable as used herein with reference to ingredients in the compositions of the application, means that the ingredient is physically and chemically compatible with the ingredients described herein, and/or should not otherwise unduly impair composition stability, aesthetics, and/or performance. Selections for suitable ingredients can be made by a person skilled in the art.
- the second component as used herein is chemically different from the other components or first component.
- a “third” component is different from the other, first, and second components, and further enumerated or “additional” components are similarly different.
- alkyl as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups.
- the number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “C n1-n2 ”.
- C 1-6 alkyl means an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. All alkyl groups are optionally fluorosubstituted unless otherwise stated.
- alkylene as used herein, whether it is used alone or as part of another group, means a straight or branched chain, saturated alkylene group, that is, a saturated carbon chain that contains substituents on two of its ends.
- the number of carbon atoms that are possible in the referenced alkylene group are indicated by the prefix “C n1-n2 ”.
- C 1-10 alkylene means an alkylene group having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. All alkylene groups are optionally fluorosubstituted unless otherwise stated.
- pharmaceutically acceptable means compatible with the treatment of subjects, for example humans.
- pharmaceutically acceptable carrier means a non-toxic solvent, dispersant, excipient, adjuvant, or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to a subject.
- pharmaceutically acceptable salt means either an acid addition salt or a base addition salt which is suitable for, or compatible with, the treatment of subjects.
- the selection criteria for the appropriate salt will be known to one skilled in the art (see, for example, S. M. Berge, et aI., “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19).
- An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound.
- Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include mono-, di-, and tricarboxylic acids.
- organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid, and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and 2-hydroxyethanesulfonic acid.
- acetic, trifluoroacetic, propionic glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic,
- Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated, solvated, or substantially anhydrous form.
- acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example, in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- a base addition salt suitable for, or compatible with, the treatment of subjects is any base addition salt suitable for, or compatible with, the treatment of subjects.
- Non-toxic organic or inorganic base addition salt of any acidic compound include, for example, compounds comprising a carboxylic acid group.
- Acidic compounds that form a basic addition salt include, for example, compounds comprising a carboxylic acid group.
- Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide as well as ammonia.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as isopropylamine, methylamine, trimethylamine, picoline, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
- Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
- Prodrugs of the compounds of the present application may be, for example, conventional esters formed with available hydroxy, thiol, amino, or carboxyl groups.
- available hydroxy or amino groups may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g., an acid chloride in pyridine).
- inert solvent e.g., an acid chloride in pyridine.
- Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C 1 -C 24 ) esters, acyloxymethyl esters, carbamates, and amino acid esters.
- solvate means a compound, or a salt or prodrug of a compound, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
- a suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water, and the like. When water is the solvent, the molecule is referred to as a “hydrate”.
- solvates of the compounds of the application will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art.
- subject as used herein includes all members of the animal kingdom including mammals, and suitably refers to humans. Thus, the methods and compositions of the present application are applicable to both human therapy and veterinary applications.
- body as used herein includes all parts of, or on, the subject's body.
- beneficial or desired clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable.
- Treating” and “treatment” may also mean prolonging survival as compared to expected survival if not receiving treatment.
- Treating” and “treatment” as used herein may also include prophylactic treatment. Treatment methods comprise administering to a subject a therapeutically effective amount of one or more of the active agents or compositions and optionally consist of a single administration, or alternatively comprise a series of administrations.
- the term “effective amount” or “therapeutically effective amount” means an amount of one or more active agents that is effective, at dosages and for periods of time necessary to achieve the desired result.
- administered means administration of a therapeutically effective amount of one or more compositions of the application to a cell, tissue, organ, or subject.
- coacervate is used herein to describe an aggregate of surfactant and polymer held together by hydrophobic and/or ionic forces, particularly an aggregate of an anionic surfactant and cationic polymer, which may be solubilized in an aqueous surfactant matrix as defined herein and which may precipitate out of solution upon the addition of excess water, e.g., through lathering or rinsing.
- active pharmaceutical agent active pharmaceutical ingredient
- active ingredient active ingredient
- API active ingredient
- active agent or API can refer to any substance used in a finished pharmaceutical product intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have direct effect in restoring, correcting, or modifying physiological functions in human beings (see World Health Organization, Working Document QAS 11.426 Rev 1).
- rinse-off composition refers to a composition suitable for being used on, administered, or applied topically to a subject and subsequently removed by rinsing with a liquid such as water.
- rinse-off may be used interchangeably with “wash-off”.
- Rinsing means substantially all of the composition (and, if applicable, extraneous debris) is removed or washed off.
- the term “substantially” in this context means that all or almost all of the composition is removed, i.e., less than 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of the composition remains after rinsing.
- Washing or “removing” also includes the use of wipes or clothes to facilitate washing or removing, especially for soaps and other related products.
- aqueous surfactant matrix refers to a composition comprising one or more surfactants and one or more polymers that are soluble in an aqueous solvent and is suitable for use in rinse-off compositions.
- oil phase refers to an ingredient or a combination of ingredients that are insoluble in water (e.g., solubility of less than about 10 mg/mL at 20° C. and atmospheric pressure).
- aqueous phase refers to an ingredient or a combination of ingredients that are soluble in water (e.g., solubility of greater than about 10 mg/mL at 20° C. and atmospheric pressure).
- water-immiscible solvents refers to solvents that are insoluble in water (e.g., have a solubility of less than about 10 mg/mL at 20° C. and atmospheric pressure).
- halobetasol propionate or “HBP” as used herein refers to a compound of the formula
- the present application relates to a rinse-off composition
- a rinse-off composition comprising
- the present application relates to a shampoo composition
- a shampoo composition comprising
- the rinse-off composition is administered or used by topical application to the body, for example, on the skin, scalp, hair, and/or another anatomical surface.
- the body is either wet or dry when the rinse-off composition is administered or used.
- the body is wetted with water prior to the administration or use of the composition.
- the rinse-off composition is lathered using water after administration or use, and before or during being removed by rinsing (e.g., being rinsed off).
- the removing by rinsing does not remove a substantial amount of any active agent(s) comprised in the rinse-off composition, for example, due to deposition of the active agent(s) on the body prior to or during rinsing.
- the amount of active agent(s) deposited on the body is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition.
- the amount of active agent(s) deposited on the body, for example on the skin, scalp, hair, and/or another anatomical surface is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the body, for example on the skin, scalp, hair, and/or another anatomical surface of a comparator composition (see, for instance, Example 3 and Clobex Rep. comparator).
- the rinse-off composition is selected from a hair care composition, a personal care composition, and a skincare composition, and combinations thereof.
- the rinse-off composition is selected from a cleansing composition, a conditioning composition, a moisturizing composition, and a shaving composition, and combinations thereof.
- the cleansing composition includes, but not is not limited to, facial, hand, and body cleansers or washes, and bath and shower products such as washes, foams, and gels.
- the hair care composition is a shampoo composition and/or hair conditioning composition.
- the shaving composition is a shaving gel, and/or shaving foam.
- the rinse-off composition may be a drug, cosmetic, and/or homeopathic product.
- the drug product may be a prescription or over-the-counter product.
- the aqueous surfactant matrix comprises one or more surfactants and one or more polymers.
- the aqueous surfactant matrix comprises one or more surfactants and one or more polymers dispersed or dissolved in water.
- the aqueous surfactant matrix comprises one or more anionic surfactants and one or more cationic polymers.
- the aqueous surfactant matrix comprises one or more anionic surfactants and one or more cationic polymers that form coacervates. While not wishing to be limited by theory, in some embodiments, the coacervates facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the body, for example skin, scalp, hair, and/or another anatomical surface.
- the aqueous surfactant matrix comprises water, one or more surfactants, one or more polymers, and is devoid of, or substantially free from ethanol and/or other water-miscible organic solvents.
- the one or more polymers are hydrophilic polymers.
- the aqueous surfactant matrix comprises:
- the cleansing property of the rinse-off compositions of the application is principally provided by the primary surfactant system which typically comprises one or more anionic surfactants.
- the anionic surfactants should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance.
- Suitable anionic surfactants for use in the rinse-off compositions herein include those that are known for use in hair care or other personal care cleansing compositions.
- the one or more anionic surfactants are selected from surfactant classes known as alkyl sulfates, alkyl ether sulfates, sulfate esters of an alkylphenoxy polyoxyethylene ethanol, alpha-olefin sulfonates, beta-alkyloxy alkane sulfonates, alkyl arylsulfonates, alkyl carbonates, alkyl ether carboxylates, fatty acids, sulfosuccinates, alkyl ether sulfosuccinates, sarcosinates, alkyl phosphates, amino acid salts, octoxynol phosphates, nonoxynol phosphates, taurates, fatty taurides, sulfated monoglycerides, fatty acid amido polyoxyethylene sulfates, and isethionates and mixtures thereof.
- surfactant classes known as alkyl sulfates, al
- Anionic surfactants are generally present in the composition as a neutralized salt in the form of sodium salts, potassium salts, ammonium salts, lithium salts, alkyl ammonium salts, or hydroxyalkyl ammonium salts.
- Anionic surfactants are described in, for example, McCutcheon's Detergents and Emulsifiers (North American Edition and International Edition, 1994).
- the one or more anionic surfactants are selected from the anionic detersive surfactants described in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- the one or more anionic surfactants are selected from alkyl sulfates, alkyl ether sulfates, alkyl phosphates, amino acid salts such as N-acyl-L-glutamate, alpha-olefin sulfonates, alkyl sarcosinates, alkyl benzene sulfonates, acyl isethionates, alkyl sulfosuccinates and acyl methyl taurides, and mixtures thereof.
- the one or more anionic surfactants are selected from sodium lauryl sulfate, ammonium lauryl sulfate, and sodium laureth sulfate (ethoxylated lauryl sulfate) and mixtures thereof. In some embodiments, the one or more anionic surfactants are selected from sodium laureth sulfate and sodium lauryl sulfate and mixtures thereof.
- the rinse-off composition of the present application comprises about 4.0 wt % to about 12.0 wt %, about 5.0 wt % to about 9.0 wt %, about 6.0 wt % to about 8.0 wt %, or about 7.0 wt % to about 8 wt % of the one or more anionic surfactants.
- the rinse-off composition of the present application comprises less than about 12 wt %, less than about 10.0 wt %, less than about 9.0 wt %, less than about 8.0 wt %, less than about 7.0 wt %, less than about 6.0 wt %, less than about 5.0 wt %, or less than or equal to about 4.0 wt % of the one or more anionic surfactants.
- the one or more anionic surfactants are present in an amount effective to form coacervates with the one or more cationic polymers, to facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the scalp.
- cationic polymers should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance.
- Suitable cationic polymers for use in the rinse-off compositions herein include those that are known for use in hair care or other personal care cleansing compositions.
- the one or more cationic polymers are selected from cationic cellulose derivatives, cationic guar derivatives, acrylamidopropyl trimonium chloride copolymer with acrylamide, homopolymers derived from the monomer diallyldimethylammonium chloride, copolymers derived from diallyldimethylammonium chloride and acrylamide, and homopolymers or copolymers of a cationic monomer selected from:
- R 1 is H or CH 3 ; Y is O or NH; Z is C 1-6 alkylene; R 2 , R 3 , and R 4 are each independently C 1-22 alkyl or C 1-22 hydroxyalkyl; and X is a monovalent anion selected from halide and C 1-4 alkyl sulfate; and
- the one or more cationic polymers are selected from the cationic hair conditioning polymers disclosed in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- the one or more cationic polymers are selected from cationic cellulose derivatives.
- the cationic cellulose derivative is a polymeric quaternary ammonium salt derived from the reaction of hydroxyethyl cellulose with a trimethylammonium-substituted epoxide. This material is known as Polyquaternium-10 and is commercially available from AkzoNobel Surface Chemistry of Chicago, Illinois, as “CelquatTM”.
- the cationic hydroxyethyl cellulose is selected from a low viscosity (e.g., 400 cPs for a 2% aqueous solution) polyquaternium-10 polymer, and a high viscosity (e.g., 1500 cPs for a 1% aqueous solution) polyquaternium-10 polymer, and mixtures thereof.
- the cationic hydroxyethyl cellulose is a mixture of a low viscosity polyquaternium-10 polymer and a high viscosity polyquaternium-10 polymer.
- the weight ratio of the low viscosity polyquaternium-10 polymer to the high viscosity polyquaternium-10 polymer is about 2:1 to about 5:1, about 2.5:1 to about 4.5:1, or about 2.6:1 to about 4.2:1.
- the low viscosity polyquaternium-10 polymer is CelquatTM SC-240C and the high viscosity polyquaternium-10 polymer is CelquatTM SC-230M, both of which are commercially available from AkzoNobel Surface Chemistry of Chicago, Illinois.
- the rinse-off composition of the present application comprises about 0.5 wt % to about 5.0 wt %, about 1.0 wt % to about 3.0 wt %, about 1.2 wt % to about 2.5 wt %, or about 1.5 wt % to about 2 wt % of the one or more cationic polymers.
- the rinse-off composition of the present application comprises about 0.4 wt % to about 4.0 wt % of one or more low viscosity cationic polymers and about 0.1 wt % to about 1.0 wt % of one or more high viscosity surfactant polymers.
- the rinse-off composition of the present application comprises about 1 wt % to about 2.0 wt % of one or more low viscosity cationic polymers and about 0.2 wt % to about 0.5 wt % of one or more high viscosity cationic polymers.
- the one or more cationic polymers are present in an amount effective to form coacervates with the one or more anionic surfactants, to facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the body, for example skin, scalp, hair, and/or another anatomical surface.
- compositions of the application further comprise one or more amphoteric surfactants and/or one or more non-ionic surfactants.
- Suitable amphoteric and/or non-ionic surfactants for use in the rinse-off compositions herein include those which are known for use in hair care or other personal care cleansing compositions.
- the amphoteric surfactants and/or non-ionic surfactants should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance.
- the one or more amphoteric and/or nonionic polymers are selected from the amphoteric/zwitterionic and nonionic polymers disclosed in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- Amphoteric surfactants suitable for use in rinse-off compositions are well known in the art, and include those surfactants broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group such as carboxy, sulfonate, sulfate, phosphate, or phosphonate.
- suitable amphoteric surfactants include, but are not limited to, amphocarboxylates, alkyl betaines, amidoalkylbetaines, amidoalkylsultaines, amphophosphates, phosphobetaines, pyrophosphobetaines and carboxyalkyl alkyl polyamines, and mixtures thereof.
- the amphoteric surfactant is cocoamidopropyl betaine.
- the rinse-off composition of the present application comprises about 0.0 wt % to about 5.0 wt %, about 0.1 wt % to about 5.0 wt %, 0.5 wt % to about 4.5 wt %, about 2.0 wt % to about 4.0 wt %, or about 2.0 wt % to about 3.0 wt % of the one or more amphoteric surfactants.
- suitable nonionic surfactants include, but are not limited to, polysorbate 20, C 8-22 alkyl glucosides, coconut fatty acid monoethanolamides, such as cocamide MEA, and coconut fatty acid diethanolamides, and mixtures thereof.
- the non-ionic surfactant is cocomonoethanolamide.
- the rinse-off composition of the present application comprises about 0 wt % to about 2.0 wt %, about 0.05 wt % to about 2.0 wt %, 0.1 wt % to about 1.5 wt %, about 0.2 wt % to about 1.0 wt %, or about 0.3 wt % of the one or more non-ionic surfactants.
- the rinse-off composition of the present application comprises less than about 13 wt %, less than about 12 wt %, less than about 11 wt %, less than about 10 wt %, less than about 9 wt %, less than about 8 wt %, or less than about 7 wt % of total surfactants including anionic, cationic, non-ionic and amphoteric surfactants.
- the rinse-off composition of the present application further comprises one or more ionic strength adjusting agents.
- the one or more ionic strength adjusting agents are pharmaceutically acceptable alkali metal halides (e.g., potassium chloride and sodium chloride) and alkaline earth halides (e.g., CaCl 2 and MgCl 2 ) or mixtures thereof.
- the ionic strength adjusting agent is sodium chloride.
- the rinse-off composition of the present application comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.2 wt % of the one or more ionic strength adjusting agents.
- the ionic strength adjusting agent affects the structure of micelles in the formulation and thereby affects viscosity.
- the rinse-off composition of the present application further comprises
- buffers comprises one or more buffers and/or one or more pH adjusting agents.
- Buffers and pH adjusting agents are well known in the art and can be selected from any suitable such agent.
- the buffer is a citrate buffer.
- the pH adjusting agent is sodium hydroxide (NaOH).
- suitable buffers include, but are not limited to, citrate, lactate, mandelate, acetate, benzoate, tartrate, fumarate, glucuronate, glycolate, and sebacate, or salts and mixtures thereof.
- the rinse-off composition of the present application comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.2 wt % of the one or more buffers and/or one or more pH adjusting agents.
- the solvent for the aqueous surfactant matrix is water.
- the rinse-off composition of the present application comprises less than 10 wt %, less than about 5 wt %, less than about 3 wt %, less than about 1 wt %, or less than about 0.5 wt % of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents.
- the rinse-off composition of the present application is substantially free of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents.
- composition comprises less than about 1 wt %, less than about 0.5 wt %, or less than 0.1 wt % of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents.
- water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents.
- the oil phase comprises:
- the oil phase is less than about 10 wt %, less than about 5 wt %, less than about 4 wt %, less than about 3 wt %, or less than about 2.5 wt % of the rinse-off composition. In some embodiments, the oil phase is about 2 wt %, about 3 wt %, or about 3.5 wt % of the rinse-off composition.
- the oil phase comprises one or more non-polar, water-immiscible solvents, wherein the solvents have a water solubility of less than about 10 mg/ml at 20° C. and at atmospheric pressure.
- the one or more non-polar, water-immiscible solvents may be liquid at room temperature, water-insoluble, and have a HBP solubility of greater than 1% with a log P of about 1 to 6.
- the one or more non-polar, water-immiscible solvents may be water-insoluble, liquid, with a total of at least two hydrogen bond acceptors/donors, and a log P of about 1 to 6.
- the one or more non-polar, water-immiscible solvents are selected from isopropyl N-lauroyl sarcosinate, di-isopropyl adipate, peppermint oil, and coconut oil, and mixtures thereof.
- the non-polar, water-immiscible solvent is di-isopropyl adipate, optionally in combination with peppermint oil.
- the rinse-off composition of the present application comprises about 0.1 wt % to about 7.0 wt %, 0.5 wt % to about wt %, about 0.6 wt % to about 4.0 wt %, or about 0.7 wt % to about 3.0 wt % of the one or more non-polar, water-immiscible solvents.
- the one or more non-polar water-immiscible solvents comprise about 10 wt % to about 25 wt % of peppermint oil, based on the total weight of the one or more non-polar water-immiscible solvents.
- the peppermint oil is present in an amount to improve stability and/or potency of the rinse-off composition.
- the oil phase further comprises one or more water-immiscible or water-insoluble components.
- the one or more water-immiscible or water-insoluble components are selected from components that help to spread or stabilize the dispersion of the oil phase in the surfactant phase by interacting with the water to produce an aqueous gel phase at the oil/water interface.
- the one or more water-immiscible or water-insoluble components are selected from dimethicone, cyclomethicone, and fatty alcohols (such as cetostearyl, myristyl, cetyl and stearyl alcohols), and mixtures thereof.
- the oil phase comprises about 0.1 wt % to about 1.5 wt %, about 0.3 wt % to about 1.3 wt %, or about 0.5 wt % to about 1.0 wt % of the one or more water-immiscible or water-insoluble components.
- Permeation enhancers are optional ingredients of the rinse-off composition. Further, the deposition of active agents on the hair, scalp, or skin is not a factor of the permeation enhancers. Deposition and permeation/penetration of active agents can occur independent of each other.
- the oil phase further comprises one or more permeation enhancers.
- the one or more permeation enhancers are selected from methyl laurate, isopropyl myristate, oleic acid, and glyceryl oleate, and mixtures thereof.
- the compositions of the application comprise about 0.1 wt % to about 2.0 wt %, about 0.2 wt % to about 1.75 wt %, about 0.75 wt % to about 1.5 wt %, about 0.1 wt % to about 1.0 wt %, about 0.25 wt % to about 0.75 wt %, or about 1.0 wt % of the one or more permeation enhancers.
- the one or more permeation enhancers comprise methyl laurate and isopropyl myristate.
- the compositions of the application comprise about wt % to about 0.3 wt %, or about 0.25 wt % of methyl laurate; and about 0.6 wt % to about 0.9 wt %, or about 0.75 wt % of isopropyl myristate.
- the total amount of the oil phase is less than about 5 wt %, less than about 4 wt %, less than about 3 wt %, or less than about 2.5 wt % of the composition. In another embodiment, the total amount of the oil phase is about 2 wt %, about 3 wt %, or about 3.5 wt % of the composition.
- the one or more active agents are selected from any active agent that would be desirable to be topically administered to a subject.
- the one or more active agents may be selected from any active agent for the treatment of conditions affecting the skin and/or hair.
- the skin is the scalp.
- the one or more active agents are selected from drug, cosmetic, or homeopathic agents and combinations thereof.
- the one or more active agents are hydrophobic.
- the one or more active agents are selected from azelaic acid,
- retinol tranexamic acid, resorcinol, lipophilic vitamins and vitamin derivatives, cannabinoids (including cannabidiol (CBD) and/or tetrahydrocannabinol (THC)), lidocaine, and combinations thereof.
- Azelaic acid can be used for treating acne.
- retinol is used for anti-aging and/or anti-wrinkle purposes.
- tranexamic acid, resorcinol and/or lipophilic vitamins/vitamin derivatives is/are used for skin lightening and/or hyperpigmentation.
- CBD is used for skin rejuvenation and/or for treating psoriasis and pain.
- lidocaine is used for pain relief and/or as a local anesthetic.
- the one or more active agents are selected corticosteroids, such as topical corticosteroids.
- the one or more active agents are selected from hydrocortisone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, beclometasone, betamethasone, dexamethasone, fluocortolone, halometasone, mometasone, alclometasone dipropionate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clobetasone butyrate, fluprednidene acetate, mometasone furoate, ciclesonide, cortisone acetate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortis
- the corticosteroid is selected from a progestogen compound and a methasone compound, and mixtures thereof.
- a progestogen compound is a compound that belongs to the class of steroid hormones that bind to and activate the progesterone receptor, an example of which is progesterone.
- Methasones are a class of corticosteroids which are defined by substitution with a methyl group at the C16alpha or C16beta position of the pregnane steroid nucleus.
- methasones include, but are not limited to, alclometasone, amelometasone, beclometasone, betamethasone, cormetasone, desoximetasone, dexamethasone, flumetasone, halometasone, icometasone, mometasone and paramethasone, or pharmaceutically acceptable salts, solvates, and/or prodrugs thereof.
- the active agent is halobetasol propionate (HBP).
- the one or more active agents are selected from a growth-promoting agent, hair-strengthening agent and coloring agent, sunblocking agents, hair removal/depilatory agents, anti-perspirant agents, pediculosides, pesticides and a mixture thereof.
- the growth promoting agent is minoxidil.
- the one or more active agents are selected from antifungals.
- the antifungal may include, but is not limited to, azoles.
- the azoles are selected from ketoconazole, econazole, luluconazole, and mixtures thereof.
- the one or more active agents are active agents useful in the treatment of inflammatory skin disease (e.g., inflammatory scalp disease), fungal skin disease (e.g., fungal scalp disease), serborrheic dermatitis, psoriasis, dry scalp, and/or dandruff.
- inflammatory skin disease e.g., inflammatory scalp disease
- fungal skin disease e.g., fungal scalp disease
- serborrheic dermatitis e.g., psoriasis
- dry scalp e.g., dry scalp, and/or dandruff.
- Exemplary active agents useful in treating such conditions may include, but are not limited to, selenium sulfide, pyrithione zinc, terbinafine, sodium sulfacetamide, isotretinoin, tretinoic acid, tar, piroctone olamine, coal tar, sulfur, climbazole, ciclopirox olamine, ketoconazole, zinc omadine, salicylic acid, keratolyic agents, and mixtures thereof.
- the one or more actives that may be used include vitamins, including but not limited to, vitamin D, vitamin D analogs, calcipotriene, calcipotriol, vitamin A, retinoids, and mixtures thereof.
- adrenergic agent examples include the following: adrenergic agent, adrenocortical steroid, adrenocortical suppressant, aldosterone antagonist, amino acid, anabolic, analeptic, analgesic, anesthetic, anorectic, anti-acne agent, anti-adrenergic, anti-allergic, anti-amebic, anti-anemic, anti-anginal, anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, anticholinergic, anticoagulant, anticonvulsant, antidepressant, antidiabetic, antidiarrheal, antidiuretic, anti-emetic, anti-epileptic, antifibrinolytic, antifungal, antihemorrhagic, antihistamine, antihyperlipidemia, antihypertensive, antihypotensive, anti-infective, anti-inflammatory, antimicrobial, anti
- the present application excludes one or more active agents from
- the composition excludes silicone.
- the composition excludes zinc pyrithione.
- the composition may exclude silicone.
- the composition may exclude zinc pyrithione.
- the rinse-off composition of the present application comprises about 0.01 wt % to about 10.0 wt %, about 0.02 wt % to about 1.0 wt %, or about 0.03 wt % to about 0.5 wt %, or about 0.05 wt % of the one or more active agents.
- the rinse-off composition of the present application further comprises additional ingredients selected from one or more preservatives, one or more perfumes, one or more humectants, one or more foaming agents, one or more propellants, and any other ingredient used in rinse-off compositions, such as personal care or hair care compositions; and mixtures thereof. Whether these ingredients are included in the oil phase or the aqueous surfactant matrix will depend on the solubility properties of each ingredient as would be well-known to a person skilled in the art.
- the humectant is selected from glycerin,1,3-propanediol, sorbitol and other hydrocarbon polyol compounds, or combinations thereof. In some embodiments, the humectant is glycerin. In some embodiments, the rinse-off composition of the present application comprises about 0.5 wt % to about 3.0 wt %, about 1.0 wt % to about 2.5 wt %, or about 1.5 wt % to about 2.5 wt % of the one or more humectants. In some embodiments, the humectant is included in the aqueous surfactant matrix.
- the one or more preservatives are selected from any suitable preservative known in the art, such as those disclosed in Orth, Donald, Ph.D. Insights into Cosmetic Microbiology, Alluredbooks, Carol Stream I1 USA, 2010, the contents of which are incorporated herein by reference.
- the one or more preservatives of the rinse-off composition of the present application are selected from phenoxyethanolcaprylyl glycol, 1,2-hexanediol, decane-1,2-diol and mixtures thereof.
- the preservative of the rinse-off composition of the present application is phenoxyethanol or SymocideTM PC available from Symrise AG.
- the rinse-off composition comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.3 wt % of the one or more preservatives
- the rinse-off composition comprises:
- the rinse-off composition comprises:
- the rinse-off composition of the present application is non-irritating.
- the weight ratio of the oil phase to the aqueous surfactant matrix is about 1:99 to about 1:9.
- about 25% to about 50% or about 27% to about 45% of the active agent is solubilized in the one or more non-polar water-immiscible solvents.
- the active is present in the composition in non-particulate and solubilized form.
- the compositions of the application have an acceptable shelf life of greater than about 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the compositions of the application have an acceptable shelf life that is greater than about 12, 24, or 36 months. In some embodiments, the shelf life is determined at International Council for Harmonisation (ICH) long-term storage conditions by;
- the rinse-off composition of the application comprises greater than about 95% or about 96% of the original amount of the one or more active agents after storage at for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the rinse-off composition of the application comprises greater than about 95%, 96%, 97%, or 98% of the original amount of the one or more active agents after storage at 25° C. for 3, 6, 9, 12, or 24 months.
- the rinse-off composition of the application comprises less than about 2% or 3% of impurities after storage at 45° C. for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the rinse-off composition of the application comprises less than about 1% or 2% of impurities after storage at 25° C. for 3, 6, 9, 12, or 24 months.
- the rinse-off compositions of the application do not contain particulates. In some embodiments, the rinse-off compositions of the application do not change appearance after storage at 25° C. or 45° C. for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months.
- the rinse-off composition provides a deposition of the one or more active agents onto an applied surface (such as the scalp of a subject) that is about 5% to about 30% of the total amount of the one or more active agents in the composition. In some embodiments, the rinse-off composition provides a deposition of the one or more active agents onto the applied surface that is about 10% to about 25% of the total amount of the one or more active agents in the composition.
- the rinse-off composition provides a deposition of the one or more active agents onto the applied surface that is greater than about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the total amount of the one or more active agents in the composition.
- the rinse-off composition has a pH of about 5.5 to about 7 or about 5.6 to about 6.5.
- the rinse-off compositions of the present application exhibit favorable reviews in actual in use (wear) studies on subjects, including human subjects.
- the rinse-off compositions exhibit good lathering characteristics, good rinsing characteristics, good fragrance characteristics, and/or good viscosity characteristics in wear studies on subjects, including human subjects.
- the rinse-off compositions of the application rank higher in wear studies than other commercially available rinse-off compositions comprising one or more active agents, such as the shampoo ClobexTM.
- the wear study comprises having the subject wet one or more body parts where the rinse-off composition is to be applied; dispense an appropriate amount of the rinse-off composition in the subject's palm, such as one to three teaspoons or an amount suitable for the size of one or more body parts; and apply the rinse-off composition to the subject's one or more body parts, massaging with fingers to ensure that the composition is in contact with the one or more body parts.
- the subject then leaves the rinse-off composition in contact with the one or more body parts for at least 5 minutes but no more than 10 minutes, followed by adding more water to the composition, massaging to create a lather; and rinsing.
- the wear study comprises having the subject wet their scalp and hair, for example in a shower; dispense about one teaspoon (5 mL) of the shampoo composition in the subject's palm and apply the shampoo composition to the subject's scalp; and massaging with fingers to ensure that the shampoo is in contact with the scalp (not just hair).
- the subject then leaves the shampoo in contact with the scalp for at least 5 minutes but no more than 10 minutes, followed by adding more water to the shampoo, massaging to create a lather, and rinsing.
- the present application relates to a method of topically administering one or more active agents to a subject in need thereof comprising:
- the present application includes a method of topically administering one or more active agents to a subject in need thereof comprising:
- the present application relates to a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
- the present application includes a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
- the time period between step a) and step b) of the methods of the present application is less than 15 minutes, less than 10 minutes, or about 5 minutes. In another embodiment, the time period between step a) and step c) of the methods of the present application is less than 15 minutes, less than 10 minutes, or about 5 minutes.
- the rinse-off compositions of the present application exhibit improved active agent deposition when compared to a comparative formulation.
- the comparative formulation is HBP Clobex Replicate (or Clobex HBP System) (see Examples).
- the amount of active agent(s) deposited on the skin, scalp, or hair by the compositions of the present application is at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times greater than a comparative formulation.
- the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) of the methods of the application is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition.
- the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) of the methods of the application is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface, of a comparator composition.
- the time period between step a) and b) of the methods of the application is less than 15 minutes, less than 10 minutes, or about 5 minutes and the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition.
- the time period between step a) and b) of the methods of the application is less than 15 minutes, less than 10 minutes, or about 5 minutes and the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the skin, scalp, or hair of a comparator composition.
- the present application relates to a method of treating and/or preventing a disease, disorder, or condition; or treating and/or preventing symptoms of a disease, disorder, or condition, with one or more active agents comprising:
- the present application includes a method of treating and/or preventing a disease, disorder, or condition; or treating and/or preventing symptoms of a disease, disorder, or condition, with one or more active agents comprising:
- the present application relates to a method of the body of a subject in need thereof comprising:
- the present application relates to a method of cleansing hair, scalp, and/or skin of a subject in need thereof comprising:
- the present application includes a method of cleansing hair and scalp of a subject in need thereof comprising:
- the present application relates to a use of a rinse-off composition of the present application for the administration of one or more active agents to a subject in need thereof.
- the present application includes a use of a shampoo composition of the present application for the administration of one or more active agents to a subject in need thereof.
- the present application relates to a use of a rinse-off composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- the present application includes a use of a shampoo composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- the present application relates to a use of a rinse-off composition of the present application to cleanse the body of a subject in need thereof.
- the present application relates to a use of a rinse-off composition of the present application to cleanse hair, scalp, and/or skin of a subject in need thereof.
- the present application relates to a use of a shampoo composition of the present application to cleanse hair and scalp of a subject in need thereof.
- the rinse-off composition is used on or applied to the body of the subject. In some embodiments, the rinse-off composition is used on or applied to the skin of the subject. In some embodiments, the rinse-off composition is used on or applied to the hair, scalp, or skin of the subject. In some embodiment, the rinse-off composition is used, or applied to the subject for less than 5 to 15 minutes prior to the optional lathering and the rinsing. In some embodiments, the rinse-off composition is used or applied to the subject for less than 10 minutes prior to the optional lathering and the rinsing. In some embodiments, the rinse-off composition is used or applied to the subject for less than 5 minutes prior to the optional lathering and the rinsing.
- an effective amount of the rinse-off composition is used or applied, wherein the effective amount is an amount effective to treat a disease, disorder, or condition treatable with the one or more active agents and/or to treat symptoms of a disease, disorder, or condition treatable with the one or more active agents.
- the one or more active agents is a corticosteroid and the condition treatable with the active agent is selected from dandruff, seborrheic dermatitis, and/or psoriasis.
- the one or more active agents are useful in treating inflammatory skin diseases, inflammatory scalp disease, fungal skin disease, fungal scalp disease, serborrheic dermatitis, psoriasis, dry skin, dry scalp, and/or dandruff.
- the rinse-off compositions may be applied or used at least once a day.
- the rinse-off compositions are applied or used from about one time per week to 6 times per week.
- the rinse-off compositions are applied or used about one time per week to about once or about twice daily.
- the rinse-off compositions are applied or used one time per week to one time per two weeks, one time per three weeks, one time per four weeks, or one time per month.
- the rinse-off compositions are applied or used one time per day, two times per day, three times per day, or four times per day.
- the length and timing of the treatments depends on a variety of factors, such as the severity of the disease, disorder or condition, the age of the subject, the concentration and/or the activity of the one or more active agents, and/or a combination thereof. It will also be appreciated that the effective amount of the rinse-off composition used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration is required. For example, the rinse-off compositions may be administered or used in an amount and for duration sufficient to treat the subject.
- an effective amount is an amount that, for example, treats the disease, disorder, or condition compared to the treatment without administration or use of the rinse-off compositions of the application.
- effective amounts vary according to factors such as the disease state, age, sex, and/or weight of the subject.
- the amount of a given composition that will correspond to an effective amount will vary depending upon factors, such as the given active agent(s), the composition, the type of condition, disease or disorder, the identity of the subject being treated, and the like, but can nevertheless be routinely determined by one skilled in the art.
- compositions of the present application are used in the context of, with, or as part of a device.
- the device is to facilitate use, application, or administration of the composition, for example, but not limited to, a foaming device, an aerosol device, a pump device, a roll-on device, or any other suitable applicator, including brush, comb, sponge, pad, and the like.
- the compositions of the present application are used for cosmetic purposes.
- Clobex shampoo would be expected to have a deleterious effect upon the lathering of a shampoo and may cause irritation if left too long on the skin, but is likely incorporated in the product to help solubilize CP as well as increase the skin absorption of the drug during the 15 minute “leave-on” period instructed in the Clobex product label.
- Example 2 Exemplary Compositions of the Present Application
- compositions were prepared using varying surfactant types and levels, varying levels of cationic polymers, and varying types and levels of water-insoluble oil phase solvents.
- Compositions HA, HA-2, and CA (shown in Table 2) used a lower total amount of cationic polymer and increased surfactant levels relative to Composition AA (shown in Table 2), but had modifications to the oil phase to improve lathering and rheology.
- the total oil phase level was reduced and cetostearyl alcohol and cyclomethicone were removed.
- the level of di-isopropyl adipate was minimized to that required to solubilize HBP, HA and CA included and peppermint oil to help solubilize HBP.
- Clobex HBP Replica and Compositions AA, HA, and CA were evaluated for amount of drug deposited in vitro onto human cadaver skin mounted in 15 mm diameter Franz cells maintained at about 35° C. using the following simulated shampooing protocol:
- Table 3 summarizes the amount of HBP detected on the skin surface after 24 hours, which may be considered the amount of drug deposited from the composition during application. All three compositions had considerably higher HBP amounts on after 24 hours than the Clobex Replicate. This suggests that the approach of incorporating HBP in a dispersed oil phase in the shampoo matrix is superior in depositing HBP than the approach used in Clobex of solubilizing the drug in a surfactant matrix containing a relatively high level of ethanol (10%). Composition AA yielded most favorable results.
- Tables 4 through 7 provide a summary of the available stability data at three months for Clobex HBP Replica and compositions AA, HA, and CA at 25° C. and 45° C. (accelerated conditions).
- Clobex replicate with HBP was clear, and the other final compositions were slightly opaque.
- the Clobex replicate and formulations HA and CA appeared to be physically stable through three months at 25° C. and 45° C.
- Composition AA was stable through three months at 45° C. (accelerated conditions).
- HBP stability (Table 6) and presence of impurities (Table 7) were assessed for compositions AA, HA and CA (API), along with the Clobex HBP replica at both 25° C. and 45° C.
- Clobex HBP Replica and compositions AA, HA, and CA (API) formulations were evaluated for in-use properties by seven patients using the following instructions:
Abstract
The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.
Description
- The present application is a continuation of U.S. patent application Ser. No. 17/168,998, filed Feb. 5, 2021, which is a continuation of U.S. patent application Ser. No. 16/820,128, filed Mar. 16, 2020, now U.S. Pat. No. 10,945,952, which claims the benefit of priority from U.S. Provisional Patent Application No. 62/818,366, filed Mar. 14, 2019, the contents of each of which are incorporated herein by reference in their entirety.
- The present application pertains to rinse-off compositions useful, for example, for the delivery and deposition of active agents, such as active pharmaceutical ingredients (APIs), in particular hydrophobic APIs. More specifically, the application is directed to a rinse-off composition, such as a shampoo composition, comprising an oil phase and an aqueous surfactant matrix wherein one or more active agents are dissolved in the oil phase, as well as methods and uses thereof for delivering the one or more active agents to a subject.
- Delivery of hydrophobic and poorly soluble APIs in a surfactant-rich and aqueous based composition may be challenging due, for example, to the instability of such compositions and poor solubility of the API in such media. This problem is accentuated in personal care products such as rinse-off compositions including shampoo, where ideally the product is applied only for a short amount of time, enough to allow appropriate foaming and rinsing off, but there is a need to deposit sufficient API on the hair and skin during product application to permit diffusion of the API to the site of pharmacological action.
- For users with skin conditions such as dermatitis or psoriasis in their scalp, the development of an effective API-containing rinse-off delivery system such as a shampoo is particularly challenging since many APIs such as corticosteroids (e.g., clobetasol propionate, halobetasol propionate) are highly hydrophobic and water-insoluble.
- Currently, there exists on the market one shampoo product containing clobetasol propionate, Clobex™ from Galderma, that treats psoriatic lesions in the scalp. However, this composition requires that the shampoo be applied to the scalp and left on for 15 minutes before lathering and rinsing. This length of time presents a significant inconvenience to the user as the typical shower time in the United States based upon Environmental Protection Agency (EPA) estimates is about eight minutes.
- U.S. Pat. No. 6,495,498 B2 discloses a shampoo composition comprising a water-soluble silicone agent, a cationic conditioning agent and a detergent for the delivery of benefit agents. However, this patent does not disclose the solubilization of active agents in an oil phase.
- U.S. Pat. No. 4,835,148 discloses a rinse-off shampoo composition targeting skin disorders of the scalp that requires insoluble particulates of API to come out of suspension upon dilution during hair wash thus depositing onto the scalp. This method of delivery is usually ineffective for APIs that need to permeate the skin to have therapeutic effect, since water-insoluble particulates generally do not diffuse to the site of pharmacological action nor produce pharmacological activity, and must undergo dissolution in sebum in situ before such diffusion and activity can occur.
- U.S. Pat. No. 6,183,757 B1 discloses a rinse-off antimicrobial cleansing composition comprising an antimicrobial active, an anionic surfactant and cationic polymers as deposition aids in an aqueous composition. However, this patent fails to teach solubilization of hydrophobic APIs in a water-immiscible oil phase.
- There is a need to develop a composition containing a hydrophobic API for personal care products, such as shampoo for hair cleansing and other rinse-off products, that is convenient to use (e.g., short leave-on time) and allows for deposition of said API onto the skin and hair and subsequent diffusion to a site at which it exerts its pharmacological activity.
- Rinse-off compositions containing hydrophobic, water-insoluble active agents dissolved in a water-insoluble oil phase are disclosed herein for topical dermatologic use. Rinse-off compositions of the present application have reduced topical application time compared to current rinse-off compositions comprising water-insoluble hydrophobic active agents, e.g., those dissolved in a hydroalcoholic surfactant matrix. The compositions also have improved stability, active agent deposition amounts, and/or score favorably in actual in use (wear) studies on subjects.
- Accordingly, in one aspect, the present application relates to a rinse-off composition comprising:
-
- a) an oil phase; and
- b) an aqueous surfactant matrix,
wherein the oil phase comprises one or more active agents dissolved in one or more non-polar, water-immiscible solvents and the oil phase is dispersed in the aqueous surfactant matrix.
- In another aspect, the present application relates to a method of topically administering
- one or more active agents to a subject in need thereof:
-
- a) topically applying a rinse-off composition of the present application to the subject;
- b) adding water and optionally creating lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
-
- a) topically applying a rinse-off composition comprising halobetasol propionate to the subject;
- b) adding water and optionally creating lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a method of treating and or
- preventing a disease, disorder, or condition, or symptoms thereof, with an active agent comprising:
-
- a) topically applying a rinse-off composition of the present application to a subject in need thereof;
- b) adding water and optionally creating lather; and
- c) rinsing the composition,
wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- In another aspect, the present application relates to a method of cleansing hair, scalp, skin and/or other anatomical surface of a subject in need thereof comprising:
-
- a) topically applying a rinse-off composition of the present application to the subject;
- b) adding water and optionally creating lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application to administer one or more active agents to a subject in need thereof.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application to cleanse hair, scalp, skin, and/or other anatomical surface of a subject in need thereof.
- Other features and advantages of the present application will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the application, are given by way of illustration only and the scope of the claims should not be limited by these embodiments, but should be given the broadest interpretation consistent with the description as a whole.
- Unless otherwise indicated, the definitions and embodiments described in this and other
- sections are intended to be applicable to all embodiments and aspects of the present application herein described for which they are suitable as would be understood by a person skilled in the art.
- The term “composition(s) of the application” or “composition(s) of the present application” and the like as used herein refers to a rinse-off composition comprising at least an oil phase, an aqueous surfactant matrix, and an active agent dissolved in the oil phase as described herein.
- The term “suitable” as used herein with reference to ingredients in the compositions of the application, means that the ingredient is physically and chemically compatible with the ingredients described herein, and/or should not otherwise unduly impair composition stability, aesthetics, and/or performance. Selections for suitable ingredients can be made by a person skilled in the art.
- The term “and/or” as used herein means that the listed items are present, or used, individually or in combination. In effect, this term means that “at least one of” or “one or more” of the listed items is used or present.
- As used in the present application, the singular forms “a”, “an” and “the” include plural references unless the content clearly dictates otherwise. For example, an embodiment including “a solvent” should be understood to present certain aspects with one solvent or two or more additional solvents.
- In embodiments comprising an “additional” or “second” component, such as an additional or second solvent, the second component as used herein is chemically different from the other components or first component. A “third” component is different from the other, first, and second components, and further enumerated or “additional” components are similarly different.
- In understanding the scope of the present application, the term “comprising” and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, ingredients, groups, integers, and/or steps, but do not exclude the presence of other unstated features, elements, components, ingredients, groups, integers, and/or steps. The foregoing also applies to words having similar meanings such as the terms, “including”, “having” and their derivatives.
- The term “consisting” and its derivatives, as used herein, are intended to be closed terms that specify the presence of the stated features, elements, components, ingredients, groups, integers, and/or steps, but exclude the presence of other unstated features, elements, components, ingredients, groups, integers, and/or steps.
- The term “consisting essentially of”, as used herein, is intended to specify the presence of the stated features, elements, components, ingredients, groups, integers, and/or steps as well as those that do not materially affect the basic and novel characteristic(s) of features, elements, components, ingredients, groups, integers, and/or steps.
- The terms “about”, “substantially”, and “approximately” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% of the modified term if this deviation would not negate the meaning of the word it modifies or unless the context suggests otherwise to a person skilled in the art.
- The present description refers to a number of chemical terms and abbreviations used by those skilled in the art. Nevertheless, definitions of selected terms are provided for clarity and consistency.
- The term “alkyl” as used herein, whether it is used alone or as part of another group, means straight or branched chain, saturated alkyl groups. The number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “Cn1-n2”. For example, the term C1-6alkyl means an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms. All alkyl groups are optionally fluorosubstituted unless otherwise stated.
- The term “alkylene” as used herein, whether it is used alone or as part of another group, means a straight or branched chain, saturated alkylene group, that is, a saturated carbon chain that contains substituents on two of its ends. The number of carbon atoms that are possible in the referenced alkylene group are indicated by the prefix “Cn1-n2”. For example, the term C1-10alkylene means an alkylene group having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. All alkylene groups are optionally fluorosubstituted unless otherwise stated.
- The term “pharmaceutically acceptable” means compatible with the treatment of subjects, for example humans.
- The term “pharmaceutically acceptable carrier” means a non-toxic solvent, dispersant, excipient, adjuvant, or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to a subject.
- The term “pharmaceutically acceptable salt” means either an acid addition salt or a base addition salt which is suitable for, or compatible with, the treatment of subjects. The selection criteria for the appropriate salt will be known to one skilled in the art (see, for example, S. M. Berge, et aI., “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19).
- An acid addition salt suitable for, or compatible with, the treatment of subjects is any non-toxic organic or inorganic acid addition salt of any basic compound. Basic compounds that form an acid addition salt include, for example, compounds comprising an amine group. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric, nitric, and phosphoric acids, as well as acidic metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include mono-, di-, and tricarboxylic acids. Illustrative of such organic acids are, for example, acetic, trifluoroacetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, mandelic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid, and other sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and 2-hydroxyethanesulfonic acid. Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated, solvated, or substantially anhydrous form. In general, acid addition salts are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection criteria for the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts such as but not limited to oxalates may be used, for example, in the isolation of compounds of the application for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- A base addition salt suitable for, or compatible with, the treatment of subjects is any
- non-toxic organic or inorganic base addition salt of any acidic compound. Acidic compounds that form a basic addition salt include, for example, compounds comprising a carboxylic acid group. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide as well as ammonia. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as isopropylamine, methylamine, trimethylamine, picoline, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
- Prodrugs of the compounds of the present application may be, for example, conventional esters formed with available hydroxy, thiol, amino, or carboxyl groups. For example, available hydroxy or amino groups may be acylated using an activated acid in the presence of a base, and optionally, in inert solvent (e.g., an acid chloride in pyridine). Some common esters which have been utilized as prodrugs are phenyl esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbamates, and amino acid esters.
- The term “solvate” as used herein means a compound, or a salt or prodrug of a compound, wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water, and the like. When water is the solvent, the molecule is referred to as a “hydrate”. The formation of solvates of the compounds of the application will vary depending on the compound and the solvate. In general, solvates are formed by dissolving the compound in the appropriate solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions. The selection of suitable conditions to form a particular solvate can be made by a person skilled in the art.
- The term “subject” as used herein includes all members of the animal kingdom including mammals, and suitably refers to humans. Thus, the methods and compositions of the present application are applicable to both human therapy and veterinary applications.
- The term “body” as used herein includes all parts of, or on, the subject's body.
- The term “treating” or “treatment” as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. In some embodiments, beneficial or desired clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. “Treating” and “treatment” may also mean prolonging survival as compared to expected survival if not receiving treatment. “Treating” and “treatment” as used herein may also include prophylactic treatment. Treatment methods comprise administering to a subject a therapeutically effective amount of one or more of the active agents or compositions and optionally consist of a single administration, or alternatively comprise a series of administrations.
- As used herein, the term “effective amount” or “therapeutically effective amount” means an amount of one or more active agents that is effective, at dosages and for periods of time necessary to achieve the desired result.
- The term “administered” as used herein means administration of a therapeutically effective amount of one or more compositions of the application to a cell, tissue, organ, or subject.
- The term “coacervate” is used herein to describe an aggregate of surfactant and polymer held together by hydrophobic and/or ionic forces, particularly an aggregate of an anionic surfactant and cationic polymer, which may be solubilized in an aqueous surfactant matrix as defined herein and which may precipitate out of solution upon the addition of excess water, e.g., through lathering or rinsing.
- The terms “active pharmaceutical agent”, “active agent”, “active pharmaceutical ingredient”, “active ingredient”, “API”, or “APIs” and the like as used herein, are intended to refer to any compound or mixture of compounds, or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, that is capable of exerting a useful pharmacological or beneficial effect. For example, active agent or API can refer to any substance used in a finished pharmaceutical product intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have direct effect in restoring, correcting, or modifying physiological functions in human beings (see World Health Organisation, Working Document QAS 11.426 Rev 1).
- The term “rinse-off composition” as used herein refers to a composition suitable for being used on, administered, or applied topically to a subject and subsequently removed by rinsing with a liquid such as water. The term “rinse-off” may be used interchangeably with “wash-off”.
- The term “rinse” or “rinsing” as used herein means to remove or wash a composition
- from or off a subject using a liquid such as water. Rinsing means substantially all of the composition (and, if applicable, extraneous debris) is removed or washed off. The term “substantially” in this context means that all or almost all of the composition is removed, i.e., less than 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of the composition remains after rinsing. “Washing” or “removing” also includes the use of wipes or clothes to facilitate washing or removing, especially for soaps and other related products.
- The term “aqueous surfactant matrix” as used herein refers to a composition comprising one or more surfactants and one or more polymers that are soluble in an aqueous solvent and is suitable for use in rinse-off compositions.
- The term “oil phase” as used herein refers to an ingredient or a combination of ingredients that are insoluble in water (e.g., solubility of less than about 10 mg/mL at 20° C. and atmospheric pressure).
- The term “aqueous phase” as used herein refers to an ingredient or a combination of ingredients that are soluble in water (e.g., solubility of greater than about 10 mg/mL at 20° C. and atmospheric pressure).
- The term “water-immiscible solvents” as used herein refers to solvents that are insoluble in water (e.g., have a solubility of less than about 10 mg/mL at 20° C. and atmospheric pressure).
- The term “halobetasol propionate” or “HBP” as used herein refers to a compound of the formula
- or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.
- In one aspect, the present application relates to a rinse-off composition comprising
-
- a) an oil phase; and
- b) an aqueous surfactant matrix,
wherein the oil phase comprises one or more active agents dissolved in one or more non-polar, water-immiscible solvents and the oil phase is dispersed in the aqueous surfactant matrix.
- In one aspect, the present application relates to a shampoo composition comprising
-
- a) an oil phase; and
- b) an aqueous surfactant matrix,
wherein the oil phase comprises one or more active agents dissolved in one or more non-polar, water-immiscible solvents and the oil phase is dispersed in the aqueous surfactant matrix.
- In some embodiments, the rinse-off composition is administered or used by topical application to the body, for example, on the skin, scalp, hair, and/or another anatomical surface. The body is either wet or dry when the rinse-off composition is administered or used. Optionally, the body is wetted with water prior to the administration or use of the composition. Optionally, the rinse-off composition is lathered using water after administration or use, and before or during being removed by rinsing (e.g., being rinsed off). In some embodiment, the removing by rinsing does not remove a substantial amount of any active agent(s) comprised in the rinse-off composition, for example, due to deposition of the active agent(s) on the body prior to or during rinsing. In one embodiment, the amount of active agent(s) deposited on the body, for example on the skin, scalp, hair, and/or other anatomical surface is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition. In another embodiment, the amount of active agent(s) deposited on the body, for example on the skin, scalp, hair, and/or another anatomical surface is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the body, for example on the skin, scalp, hair, and/or another anatomical surface of a comparator composition (see, for instance, Example 3 and Clobex Rep. comparator).
- In some embodiments, the rinse-off composition is selected from a hair care composition, a personal care composition, and a skincare composition, and combinations thereof. In some embodiments, the rinse-off composition is selected from a cleansing composition, a conditioning composition, a moisturizing composition, and a shaving composition, and combinations thereof. In some embodiments, the cleansing composition includes, but not is not limited to, facial, hand, and body cleansers or washes, and bath and shower products such as washes, foams, and gels. In some embodiments, the hair care composition is a shampoo composition and/or hair conditioning composition. In some embodiments, the shaving composition is a shaving gel, and/or shaving foam.
- In some embodiments, the rinse-off composition may be a drug, cosmetic, and/or homeopathic product. In some embodiments, the drug product may be a prescription or over-the-counter product.
- Aqueous Surfactant Matrix
- In some embodiments, the aqueous surfactant matrix comprises one or more surfactants and one or more polymers.
- In some embodiments, the aqueous surfactant matrix comprises one or more surfactants and one or more polymers dispersed or dissolved in water.
- In some embodiments, the aqueous surfactant matrix comprises one or more anionic surfactants and one or more cationic polymers.
- In some embodiments, the aqueous surfactant matrix comprises one or more anionic surfactants and one or more cationic polymers that form coacervates. While not wishing to be limited by theory, in some embodiments, the coacervates facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the body, for example skin, scalp, hair, and/or another anatomical surface.
- In some embodiments, the aqueous surfactant matrix comprises water, one or more surfactants, one or more polymers, and is devoid of, or substantially free from ethanol and/or other water-miscible organic solvents.
- In some embodiments, the one or more polymers are hydrophilic polymers.
- In some embodiments, the aqueous surfactant matrix comprises:
-
- a) one or more anionic surfactants;
- b) one or more cationic polymers;
- c) one or more amphoteric surfactants and/or one or more non-ionic surfactants;
- d) one or more ionic strength adjusting agents;
- e) water; and
- f) optionally, one or more preservatives, humectants, buffers, and/or pH adjusting agents.
- Anionic Surfactants
- The cleansing property of the rinse-off compositions of the application is principally provided by the primary surfactant system which typically comprises one or more anionic surfactants. The anionic surfactants should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance. Suitable anionic surfactants for use in the rinse-off compositions herein include those that are known for use in hair care or other personal care cleansing compositions. In some embodiments, the one or more anionic surfactants are selected from surfactant classes known as alkyl sulfates, alkyl ether sulfates, sulfate esters of an alkylphenoxy polyoxyethylene ethanol, alpha-olefin sulfonates, beta-alkyloxy alkane sulfonates, alkyl arylsulfonates, alkyl carbonates, alkyl ether carboxylates, fatty acids, sulfosuccinates, alkyl ether sulfosuccinates, sarcosinates, alkyl phosphates, amino acid salts, octoxynol phosphates, nonoxynol phosphates, taurates, fatty taurides, sulfated monoglycerides, fatty acid amido polyoxyethylene sulfates, and isethionates and mixtures thereof. Anionic surfactants are generally present in the composition as a neutralized salt in the form of sodium salts, potassium salts, ammonium salts, lithium salts, alkyl ammonium salts, or hydroxyalkyl ammonium salts. Many additional suitable surfactants are described in, for example, McCutcheon's Detergents and Emulsifiers (North American Edition and International Edition, 1994).
- In some embodiments, the one or more anionic surfactants are selected from the anionic detersive surfactants described in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- In some embodiments, the one or more anionic surfactants are selected from alkyl sulfates, alkyl ether sulfates, alkyl phosphates, amino acid salts such as N-acyl-L-glutamate, alpha-olefin sulfonates, alkyl sarcosinates, alkyl benzene sulfonates, acyl isethionates, alkyl sulfosuccinates and acyl methyl taurides, and mixtures thereof. In some embodiments, the one or more anionic surfactants are selected from sodium lauryl sulfate, ammonium lauryl sulfate, and sodium laureth sulfate (ethoxylated lauryl sulfate) and mixtures thereof. In some embodiments, the one or more anionic surfactants are selected from sodium laureth sulfate and sodium lauryl sulfate and mixtures thereof.
- In some embodiments, the rinse-off composition of the present application comprises about 4.0 wt % to about 12.0 wt %, about 5.0 wt % to about 9.0 wt %, about 6.0 wt % to about 8.0 wt %, or about 7.0 wt % to about 8 wt % of the one or more anionic surfactants. In other embodiments, the rinse-off composition of the present application comprises less than about 12 wt %, less than about 10.0 wt %, less than about 9.0 wt %, less than about 8.0 wt %, less than about 7.0 wt %, less than about 6.0 wt %, less than about 5.0 wt %, or less than or equal to about 4.0 wt % of the one or more anionic surfactants.
- In some embodiments, the one or more anionic surfactants are present in an amount effective to form coacervates with the one or more cationic polymers, to facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the scalp.
- Cationic Polymers
- The cationic polymers should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance. Suitable cationic polymers for use in the rinse-off compositions herein include those that are known for use in hair care or other personal care cleansing compositions.
- In some embodiments, the one or more cationic polymers are selected from cationic cellulose derivatives, cationic guar derivatives, acrylamidopropyl trimonium chloride copolymer with acrylamide, homopolymers derived from the monomer diallyldimethylammonium chloride, copolymers derived from diallyldimethylammonium chloride and acrylamide, and homopolymers or copolymers of a cationic monomer selected from:
- (a) a monomer having the Formula I:
- wherein R1 is H or CH3; Y is O or NH; Z is C1-6alkylene; R2, R3, and R4 are each independently C1-22alkyl or C1-22hydroxyalkyl; and X is a monovalent anion selected from halide and C1-4alkyl sulfate; and
-
- (b) diallyldimethylammonium chloride,
- (c) and mixtures thereof.
- In some embodiments, the one or more cationic polymers are selected from the cationic hair conditioning polymers disclosed in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- In some embodiments, the one or more cationic polymers are selected from cationic cellulose derivatives. In some embodiments, the cationic cellulose derivative is a polymeric quaternary ammonium salt derived from the reaction of hydroxyethyl cellulose with a trimethylammonium-substituted epoxide. This material is known as Polyquaternium-10 and is commercially available from AkzoNobel Surface Chemistry of Chicago, Illinois, as “Celquat™”.
- In some embodiments, the cationic hydroxyethyl cellulose is selected from a low viscosity (e.g., 400 cPs for a 2% aqueous solution) polyquaternium-10 polymer, and a high viscosity (e.g., 1500 cPs for a 1% aqueous solution) polyquaternium-10 polymer, and mixtures thereof. In some embodiments, the cationic hydroxyethyl cellulose is a mixture of a low viscosity polyquaternium-10 polymer and a high viscosity polyquaternium-10 polymer. In some embodiments, the weight ratio of the low viscosity polyquaternium-10 polymer to the high viscosity polyquaternium-10 polymer is about 2:1 to about 5:1, about 2.5:1 to about 4.5:1, or about 2.6:1 to about 4.2:1. In some embodiments, the low viscosity polyquaternium-10 polymer is Celquat™ SC-240C and the high viscosity polyquaternium-10 polymer is Celquat™ SC-230M, both of which are commercially available from AkzoNobel Surface Chemistry of Chicago, Illinois.
- In some embodiments, the rinse-off composition of the present application comprises about 0.5 wt % to about 5.0 wt %, about 1.0 wt % to about 3.0 wt %, about 1.2 wt % to about 2.5 wt %, or about 1.5 wt % to about 2 wt % of the one or more cationic polymers. In some embodiments, the rinse-off composition of the present application comprises about 0.4 wt % to about 4.0 wt % of one or more low viscosity cationic polymers and about 0.1 wt % to about 1.0 wt % of one or more high viscosity surfactant polymers. In some embodiments, the rinse-off composition of the present application comprises about 1 wt % to about 2.0 wt % of one or more low viscosity cationic polymers and about 0.2 wt % to about 0.5 wt % of one or more high viscosity cationic polymers.
- In some embodiments, the one or more cationic polymers are present in an amount effective to form coacervates with the one or more anionic surfactants, to facilitate deposition of the non-polar water-immiscible solvent comprising the active agent on to the body, for example skin, scalp, hair, and/or another anatomical surface.
- Amphoteric and Non-ionic Surfactants
- In some embodiments, the compositions of the application further comprise one or more amphoteric surfactants and/or one or more non-ionic surfactants. Suitable amphoteric and/or non-ionic surfactants for use in the rinse-off compositions herein include those which are known for use in hair care or other personal care cleansing compositions. The amphoteric surfactants and/or non-ionic surfactants should be physically and chemically compatible with the ingredients described herein, or should not otherwise unduly impair product stability, aesthetics, or performance.
- In some embodiments, the one or more amphoteric and/or nonionic polymers are selected from the amphoteric/zwitterionic and nonionic polymers disclosed in U.S. Pat. No. 5,932,203, which is incorporated herein by reference.
- Amphoteric surfactants suitable for use in rinse-off compositions are well known in the art, and include those surfactants broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group such as carboxy, sulfonate, sulfate, phosphate, or phosphonate.
- In some embodiments, suitable amphoteric surfactants include, but are not limited to, amphocarboxylates, alkyl betaines, amidoalkylbetaines, amidoalkylsultaines, amphophosphates, phosphobetaines, pyrophosphobetaines and carboxyalkyl alkyl polyamines, and mixtures thereof. In some embodiments, the amphoteric surfactant is cocoamidopropyl betaine.
- In some embodiments, the rinse-off composition of the present application comprises about 0.0 wt % to about 5.0 wt %, about 0.1 wt % to about 5.0 wt %, 0.5 wt % to about 4.5 wt %, about 2.0 wt % to about 4.0 wt %, or about 2.0 wt % to about 3.0 wt % of the one or more amphoteric surfactants.
- In some embodiments, suitable nonionic surfactants include, but are not limited to, polysorbate 20, C8-22alkyl glucosides, coconut fatty acid monoethanolamides, such as cocamide MEA, and coconut fatty acid diethanolamides, and mixtures thereof. In some embodiments, the non-ionic surfactant is cocomonoethanolamide.
- In some embodiments, the rinse-off composition of the present application comprises about 0 wt % to about 2.0 wt %, about 0.05 wt % to about 2.0 wt %, 0.1 wt % to about 1.5 wt %, about 0.2 wt % to about 1.0 wt %, or about 0.3 wt % of the one or more non-ionic surfactants.
- In one embodiment, the rinse-off composition of the present application comprises less than about 13 wt %, less than about 12 wt %, less than about 11 wt %, less than about 10 wt %, less than about 9 wt %, less than about 8 wt %, or less than about 7 wt % of total surfactants including anionic, cationic, non-ionic and amphoteric surfactants.
- It has been identified herein that an inverse relationship between the amount of surfactant and the amount of deposition of the active agent exists in the compositions of the present application. For example, the higher the amount of total surfactant in the composition the lower the level of active agent deposition on the body, for example skin, scalp, hair, and/or another anatomical surface. Without being bound by theory, high levels of surfactant are believed to facilitate the entrapment of active agent in micelles of rinse-off formulation thereby resulting in washing out of the active agent during lathering and rinsing.
- Ionic Strength Adjusting Agents
- In some embodiments, the rinse-off composition of the present application further comprises one or more ionic strength adjusting agents. In some embodiments, the one or more ionic strength adjusting agents are pharmaceutically acceptable alkali metal halides (e.g., potassium chloride and sodium chloride) and alkaline earth halides (e.g., CaCl2 and MgCl2) or mixtures thereof. In some embodiments, the ionic strength adjusting agent is sodium chloride. In some embodiments, the rinse-off composition of the present application comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.2 wt % of the one or more ionic strength adjusting agents.
- Without being bound by theory, the ionic strength adjusting agent affects the structure of micelles in the formulation and thereby affects viscosity.
- Buffers/pH Adjusting Agents
- In some embodiments, the rinse-off composition of the present application further
- comprises one or more buffers and/or one or more pH adjusting agents. Buffers and pH adjusting agents are well known in the art and can be selected from any suitable such agent. In some embodiments, the buffer is a citrate buffer. In some embodiments, the pH adjusting agent is sodium hydroxide (NaOH). In other embodiments, suitable buffers include, but are not limited to, citrate, lactate, mandelate, acetate, benzoate, tartrate, fumarate, glucuronate, glycolate, and sebacate, or salts and mixtures thereof. In some embodiments, the rinse-off composition of the present application comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.2 wt % of the one or more buffers and/or one or more pH adjusting agents.
- Solvents
- In some embodiments, the solvent for the aqueous surfactant matrix is water. In some embodiments, the rinse-off composition of the present application comprises less than 10 wt %, less than about 5 wt %, less than about 3 wt %, less than about 1 wt %, or less than about 0.5 wt % of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents. In some embodiments, the rinse-off composition of the present application is substantially free of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents. The term “substantially free from” means that the composition comprises less than about 1 wt %, less than about 0.5 wt %, or less than 0.1 wt % of water-miscible solvents such as ethanol or other water-miscible organic solvents, including other water-miscible volatile organic solvents.
- Oil Phase
- In some embodiments, the oil phase comprises:
-
- a) one or more active agents;
- b) one or more non-polar, water-immiscible solvents;
- c) optionally, one or more water-immiscible or water-insoluble components; and
- d) optionally, one or more permeation enhancers.
- In some embodiments, the oil phase is less than about 10 wt %, less than about 5 wt %, less than about 4 wt %, less than about 3 wt %, or less than about 2.5 wt % of the rinse-off composition. In some embodiments, the oil phase is about 2 wt %, about 3 wt %, or about 3.5 wt % of the rinse-off composition.
- Non-Polar, Water-Immiscible Solvent
- In some embodiments, the oil phase comprises one or more non-polar, water-immiscible solvents, wherein the solvents have a water solubility of less than about 10 mg/ml at 20° C. and at atmospheric pressure. In some embodiments, the one or more non-polar, water-immiscible solvents may be liquid at room temperature, water-insoluble, and have a HBP solubility of greater than 1% with a log P of about 1 to 6. In some embodiments, the one or more non-polar, water-immiscible solvents may be water-insoluble, liquid, with a total of at least two hydrogen bond acceptors/donors, and a log P of about 1 to 6.
- In further embodiments, the one or more non-polar, water-immiscible solvents are selected from isopropyl N-lauroyl sarcosinate, di-isopropyl adipate, peppermint oil, and coconut oil, and mixtures thereof. In some embodiments, the non-polar, water-immiscible solvent is di-isopropyl adipate, optionally in combination with peppermint oil. In some embodiments, the rinse-off composition of the present application comprises about 0.1 wt % to about 7.0 wt %, 0.5 wt % to about wt %, about 0.6 wt % to about 4.0 wt %, or about 0.7 wt % to about 3.0 wt % of the one or more non-polar, water-immiscible solvents.
- In some embodiments, the one or more non-polar water-immiscible solvents comprise about 10 wt % to about 25 wt % of peppermint oil, based on the total weight of the one or more non-polar water-immiscible solvents. In some embodiments, the peppermint oil is present in an amount to improve stability and/or potency of the rinse-off composition.
- Water-Immiscible or Water-Insoluble Components
- In some embodiments, the oil phase further comprises one or more water-immiscible or water-insoluble components. In some embodiments, the one or more water-immiscible or water-insoluble components are selected from components that help to spread or stabilize the dispersion of the oil phase in the surfactant phase by interacting with the water to produce an aqueous gel phase at the oil/water interface. In some embodiments, the one or more water-immiscible or water-insoluble components are selected from dimethicone, cyclomethicone, and fatty alcohols (such as cetostearyl, myristyl, cetyl and stearyl alcohols), and mixtures thereof. In some embodiments, the oil phase comprises about 0.1 wt % to about 1.5 wt %, about 0.3 wt % to about 1.3 wt %, or about 0.5 wt % to about 1.0 wt % of the one or more water-immiscible or water-insoluble components.
- Permeation Enhancers
- Permeation enhancers are optional ingredients of the rinse-off composition. Further, the deposition of active agents on the hair, scalp, or skin is not a factor of the permeation enhancers. Deposition and permeation/penetration of active agents can occur independent of each other.
- In some embodiments, the oil phase further comprises one or more permeation enhancers. In some embodiments, the one or more permeation enhancers are selected from methyl laurate, isopropyl myristate, oleic acid, and glyceryl oleate, and mixtures thereof.
- In some embodiments, the compositions of the application comprise about 0.1 wt % to about 2.0 wt %, about 0.2 wt % to about 1.75 wt %, about 0.75 wt % to about 1.5 wt %, about 0.1 wt % to about 1.0 wt %, about 0.25 wt % to about 0.75 wt %, or about 1.0 wt % of the one or more permeation enhancers.
- In some embodiments, the one or more permeation enhancers comprise methyl laurate and isopropyl myristate. In some embodiments, the compositions of the application comprise about wt % to about 0.3 wt %, or about 0.25 wt % of methyl laurate; and about 0.6 wt % to about 0.9 wt %, or about 0.75 wt % of isopropyl myristate.
- In one embodiment, the total amount of the oil phase is less than about 5 wt %, less than about 4 wt %, less than about 3 wt %, or less than about 2.5 wt % of the composition. In another embodiment, the total amount of the oil phase is about 2 wt %, about 3 wt %, or about 3.5 wt % of the composition.
- Active Agents
- In some embodiments, the one or more active agents are selected from any active agent that would be desirable to be topically administered to a subject. For example, the one or more active agents may be selected from any active agent for the treatment of conditions affecting the skin and/or hair. In some embodiments, the skin is the scalp.
- In some embodiments, the one or more active agents are selected from drug, cosmetic, or homeopathic agents and combinations thereof.
- In some embodiments, the one or more active agents are hydrophobic.
- In some embodiments, the one or more active agents are selected from azelaic acid,
- retinol, tranexamic acid, resorcinol, lipophilic vitamins and vitamin derivatives, cannabinoids (including cannabidiol (CBD) and/or tetrahydrocannabinol (THC)), lidocaine, and combinations thereof. Azelaic acid can be used for treating acne. In some embodiments, retinol is used for anti-aging and/or anti-wrinkle purposes. In some embodiments, tranexamic acid, resorcinol and/or lipophilic vitamins/vitamin derivatives is/are used for skin lightening and/or hyperpigmentation. In some embodiments, CBD is used for skin rejuvenation and/or for treating psoriasis and pain. In some embodiments, lidocaine is used for pain relief and/or as a local anesthetic.
- In some embodiments, the one or more active agents are selected corticosteroids, such as topical corticosteroids. In some embodiments, the one or more active agents are selected from hydrocortisone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, beclometasone, betamethasone, dexamethasone, fluocortolone, halometasone, mometasone, alclometasone dipropionate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clobetasone butyrate, fluprednidene acetate, mometasone furoate, ciclesonide, cortisone acetate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone valerate, prednicarbate tixocortol pivalate, clocortolone pivalate, and mixtures thereof.
- In some embodiments, the corticosteroid is selected from a progestogen compound and a methasone compound, and mixtures thereof. A progestogen compound is a compound that belongs to the class of steroid hormones that bind to and activate the progesterone receptor, an example of which is progesterone. Methasones are a class of corticosteroids which are defined by substitution with a methyl group at the C16alpha or C16beta position of the pregnane steroid nucleus. Examples of methasones include, but are not limited to, alclometasone, amelometasone, beclometasone, betamethasone, cormetasone, desoximetasone, dexamethasone, flumetasone, halometasone, icometasone, mometasone and paramethasone, or pharmaceutically acceptable salts, solvates, and/or prodrugs thereof.
- In some embodiments, the active agent is halobetasol propionate (HBP).
- In some embodiments, the one or more active agents are selected from a growth-promoting agent, hair-strengthening agent and coloring agent, sunblocking agents, hair removal/depilatory agents, anti-perspirant agents, pediculosides, pesticides and a mixture thereof. In some embodiments, the growth promoting agent is minoxidil.
- In some embodiments, the one or more active agents are selected from antifungals. The antifungal may include, but is not limited to, azoles. In some embodiments, the azoles are selected from ketoconazole, econazole, luluconazole, and mixtures thereof.
- In some embodiments, the one or more active agents are active agents useful in the treatment of inflammatory skin disease (e.g., inflammatory scalp disease), fungal skin disease (e.g., fungal scalp disease), serborrheic dermatitis, psoriasis, dry scalp, and/or dandruff. Exemplary active agents useful in treating such conditions may include, but are not limited to, selenium sulfide, pyrithione zinc, terbinafine, sodium sulfacetamide, isotretinoin, tretinoic acid, tar, piroctone olamine, coal tar, sulfur, climbazole, ciclopirox olamine, ketoconazole, zinc omadine, salicylic acid, keratolyic agents, and mixtures thereof.
- In some embodiments, the one or more actives that may be used include vitamins, including but not limited to, vitamin D, vitamin D analogs, calcipotriene, calcipotriol, vitamin A, retinoids, and mixtures thereof.
- Examples of other therapeutically active agents that may be used include the following: adrenergic agent, adrenocortical steroid, adrenocortical suppressant, aldosterone antagonist, amino acid, anabolic, analeptic, analgesic, anesthetic, anorectic, anti-acne agent, anti-adrenergic, anti-allergic, anti-amebic, anti-anemic, anti-anginal, anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, anticholinergic, anticoagulant, anticonvulsant, antidepressant, antidiabetic, antidiarrheal, antidiuretic, anti-emetic, anti-epileptic, antifibrinolytic, antifungal, antihemorrhagic, antihistamine, antihyperlipidemia, antihypertensive, antihypotensive, anti-infective, anti-inflammatory, antimicrobial, antimigraine, antimitotic, antimycotic, antinauseant, antineoplastic, antineutropenic, antiparasitic, antiproliferative, antipsychotic, antirheumatic, antiseborrheic, antisecretory, antispasmodic, antithrombotic, antiulcerative, antiviral, appetite suppressant, blood glucose regulator, bone resorption inhibitor, bronchodilator, cardiovascular agent, cholinergic, depressant, diagnostic aid, diuretic, dopaminergic agent, estrogen receptor agonist, fibrinolytic, fluorescent agent, free oxygen radical scavenger, gastric acid suppressant, gastrointestinal motility effector, glucocorticoid, hair growth stimulant, hemostatic, histamine H2 receptor antagonists, hormone, hypocholesterolemic, hypoglycemic, hypolipidemic, hypotensive, imaging agent, immunizing agent, immunomodulator, immunoregulator, immunostimulant, immunosuppressant, keratolytic, LHRH agonist, mood regulator, mucolytic, mydriatic, nasal decongestant, neuromuscular blocking agent, neuroprotective, NMDA antagonist, non-hormonal sterol derivative, plasminogen activator, platelet activating factor antagonist, platelet aggregation inhibitor, psychotropic, radioactive agent, scabicide, sclerosing agent, sedative, sedative-hypnotic, selective adenosine Al antagonist, serotonin antagonist, serotonin inhibitor, serotonin receptor antagonist, steroid, thyroid hormone, thyroid inhibitor, thyromimetic, tranquilizer, amyotrophic lateral sclerosis agent, cerebral ischemia agent, Paget's disease agent, unstable angina agent, vasoconstrictor, vasodilator, wound healing agent, xanthine oxidase inhibitor, and the like.
- In some embodiments, the present application excludes one or more active agents from
- the composition. For example, in one embodiment, the composition excludes silicone. In another example, the composition excludes zinc pyrithione.
- In some embodiments, it may be preferable to exclude one or more active agents of the present application from the composition. For example, in one embodiment, the composition may exclude silicone. In another example, the composition may exclude zinc pyrithione.
- In some embodiments, the rinse-off composition of the present application comprises about 0.01 wt % to about 10.0 wt %, about 0.02 wt % to about 1.0 wt %, or about 0.03 wt % to about 0.5 wt %, or about 0.05 wt % of the one or more active agents.
- Additional Ingredients
- In some embodiments, the rinse-off composition of the present application further comprises additional ingredients selected from one or more preservatives, one or more perfumes, one or more humectants, one or more foaming agents, one or more propellants, and any other ingredient used in rinse-off compositions, such as personal care or hair care compositions; and mixtures thereof. Whether these ingredients are included in the oil phase or the aqueous surfactant matrix will depend on the solubility properties of each ingredient as would be well-known to a person skilled in the art.
- In some embodiments, the humectant is selected from glycerin,1,3-propanediol, sorbitol and other hydrocarbon polyol compounds, or combinations thereof. In some embodiments, the humectant is glycerin. In some embodiments, the rinse-off composition of the present application comprises about 0.5 wt % to about 3.0 wt %, about 1.0 wt % to about 2.5 wt %, or about 1.5 wt % to about 2.5 wt % of the one or more humectants. In some embodiments, the humectant is included in the aqueous surfactant matrix.
- In some embodiments, the one or more preservatives are selected from any suitable preservative known in the art, such as those disclosed in Orth, Donald, Ph.D. Insights into Cosmetic Microbiology, Alluredbooks, Carol Stream I1 USA, 2010, the contents of which are incorporated herein by reference. In some embodiments, the one or more preservatives of the rinse-off composition of the present application are selected from phenoxyethanolcaprylyl glycol, 1,2-hexanediol, decane-1,2-diol and mixtures thereof. In some embodiments, the preservative of the rinse-off composition of the present application is phenoxyethanol or Symocide™ PC available from Symrise AG. In some embodiments, the rinse-off composition comprises about 0.1 wt % to about 2.0 wt %, about 0.3 wt % to about 1.5 wt %, or about 0.8 wt % to about 1.3 wt % of the one or more preservatives
- Specific Compositions of the Application
- In some embodiments, the rinse-off composition comprises:
-
- a) one or more active agents;
- b) one or more anionic surfactants;
- c) one or more cationic polymers;
- d) one or more amphoteric surfactants and/or non-ionic surfactants;
- e) one or more ionic strength adjusting agents;
- f) one or more non-polar, water-immiscible solvents;
- g) optionally, one or more water-immiscible or water-insoluble components;
- h) optionally, one or more humectants;
- i) optionally, one or more permeation enhancers;
- j) optionally, one or more buffers, pH adjusting agents and/or preservatives; and
- k) the remainder being water.
- In some embodiments, the rinse-off composition comprises:
-
- a) about 4 wt % to about 12 wt % of one or more anionic surfactants;
- b) about 0.5 wt % to about 5.0 wt % of one or more cationic polymers;
- c) about 1.0 wt % to about 5.0 wt % of one or more amphoteric surfactants;
- d) optionally, about 0.1 wt % to about 1.0 wt % of one or more non-ionic surfactants;
- e) about 0.1 wt % to about 2.0 wt % of one or more ionic strength adjusting agents;
- f) optionally, about 0.1 wt % to about 2.0 wt % of one or more buffers and/or pH adjusting agents;
- g) optionally, about 0.1 wt % to about 2.0 wt % of one or more preservatives;
- h) about 0.01 wt % to about 1 wt % of one or more active agents;
- i) about 0.5 wt % to about 2.5 wt % of one or more non-polar, water-immiscible solvents;
- j) optionally, about 0.1 wt % to about 2.0 wt % of one or more water-immiscible or water-insoluble components;
- k) optionally, about 0.5 wt % to about 2.0 wt % of the one or more permeation enhancers;
- l) optionally, about 0.1 wt % to about 3.0 wt % of one or more humectants; and
- m) the remainder being water.
- In some embodiments, the rinse-off composition of the present application is non-irritating.
- In some embodiments, the weight ratio of the oil phase to the aqueous surfactant matrix is about 1:99 to about 1:9.
- In some embodiments, about 25% to about 50% or about 27% to about 45% of the active agent is solubilized in the one or more non-polar water-immiscible solvents.
- In some embodiments, the active is present in the composition in non-particulate and solubilized form.
- In some embodiments, the compositions of the application have an acceptable shelf life of greater than about 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the compositions of the application have an acceptable shelf life that is greater than about 12, 24, or 36 months. In some embodiments, the shelf life is determined at International Council for Harmonisation (ICH) long-term storage conditions by;
-
- (a) the 95% one-sided lower confidence interval of the linear regression of the assay for the one of more active agents, pharmaceutically acceptable salts, solvates, and/or prodrugs thereof;
- (b) the 95% one-sided upper confidence interval of the linear regression of the degradant products for the one or more active agents, pharmaceutically acceptable salts, solvates, and/or prodrugs thereof; or
- (c) the pH stability of the composition.
- In some embodiments, the rinse-off composition of the application comprises greater than about 95% or about 96% of the original amount of the one or more active agents after storage at for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the rinse-off composition of the application comprises greater than about 95%, 96%, 97%, or 98% of the original amount of the one or more active agents after storage at 25° C. for 3, 6, 9, 12, or 24 months.
- In some embodiments, the rinse-off composition of the application comprises less than about 2% or 3% of impurities after storage at 45° C. for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months. In some embodiments, the rinse-off composition of the application comprises less than about 1% or 2% of impurities after storage at 25° C. for 3, 6, 9, 12, or 24 months.
- In some embodiments, the rinse-off compositions of the application do not contain particulates. In some embodiments, the rinse-off compositions of the application do not change appearance after storage at 25° C. or 45° C. for 3, 6, 9, 12, 24, 30, 33, 36, 39, 42, 45, or 48 months.
- In some embodiments, the rinse-off composition provides a deposition of the one or more active agents onto an applied surface (such as the scalp of a subject) that is about 5% to about 30% of the total amount of the one or more active agents in the composition. In some embodiments, the rinse-off composition provides a deposition of the one or more active agents onto the applied surface that is about 10% to about 25% of the total amount of the one or more active agents in the composition. In some embodiments, the rinse-off composition provides a deposition of the one or more active agents onto the applied surface that is greater than about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the total amount of the one or more active agents in the composition.
- In some embodiments, the rinse-off composition has a pH of about 5.5 to about 7 or about 5.6 to about 6.5.
- In some embodiments, the rinse-off compositions of the present application exhibit favorable reviews in actual in use (wear) studies on subjects, including human subjects. In some embodiments, the rinse-off compositions exhibit good lathering characteristics, good rinsing characteristics, good fragrance characteristics, and/or good viscosity characteristics in wear studies on subjects, including human subjects. In some embodiments, the rinse-off compositions of the application rank higher in wear studies than other commercially available rinse-off compositions comprising one or more active agents, such as the shampoo Clobex™. In some embodiments, the wear study comprises having the subject wet one or more body parts where the rinse-off composition is to be applied; dispense an appropriate amount of the rinse-off composition in the subject's palm, such as one to three teaspoons or an amount suitable for the size of one or more body parts; and apply the rinse-off composition to the subject's one or more body parts, massaging with fingers to ensure that the composition is in contact with the one or more body parts. The subject then leaves the rinse-off composition in contact with the one or more body parts for at least 5 minutes but no more than 10 minutes, followed by adding more water to the composition, massaging to create a lather; and rinsing. In an embodiment where the rinse-off composition is a shampoo composition, the wear study comprises having the subject wet their scalp and hair, for example in a shower; dispense about one teaspoon (5 mL) of the shampoo composition in the subject's palm and apply the shampoo composition to the subject's scalp; and massaging with fingers to ensure that the shampoo is in contact with the scalp (not just hair). The subject then leaves the shampoo in contact with the scalp for at least 5 minutes but no more than 10 minutes, followed by adding more water to the shampoo, massaging to create a lather, and rinsing.
- In another aspect, the present application relates to a method of topically administering one or more active agents to a subject in need thereof comprising:
-
- a) topically applying a rinse-off composition of the present application to the subject;
- b) adding water and optionally creating a lather; and
- c) rinsing the composition.
- In some embodiments, the present application includes a method of topically administering one or more active agents to a subject in need thereof comprising:
-
- a) topically applying a shampoo composition of the present application to the subject;
- b) adding water to create lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
-
- a) topically applying a rinse-off composition comprising halobetasol propionate of the present application to the subject;
- b) adding water and optionally creating a lather; and
- c) rinsing the composition.
- In another aspect, the present application includes a method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
-
- a) topically applying a shampoo comprising halobetasol propionate to the subject;
- b) adding water to create lather; and
- c) rinsing the composition.
- In one embodiment, the time period between step a) and step b) of the methods of the present application is less than 15 minutes, less than 10 minutes, or about 5 minutes. In another embodiment, the time period between step a) and step c) of the methods of the present application is less than 15 minutes, less than 10 minutes, or about 5 minutes.
- The rinse-off compositions of the present application exhibit improved active agent deposition when compared to a comparative formulation. As described herein, the comparative formulation is HBP Clobex Replicate (or Clobex HBP System) (see Examples). In one embodiment, the amount of active agent(s) deposited on the skin, scalp, or hair by the compositions of the present application is at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or at least 10 times greater than a comparative formulation.
- In one embodiment, the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) of the methods of the application is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition. In another embodiment, the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) of the methods of the application is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface, of a comparator composition.
- In one embodiment, the time period between step a) and b) of the methods of the application is less than 15 minutes, less than 10 minutes, or about 5 minutes and the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface in the time period between step a) and b) is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition. In another embodiment, the time period between step a) and b) of the methods of the application is less than 15 minutes, less than 10 minutes, or about 5 minutes and the amount of active agent(s) deposited on the body, for example the skin, scalp, hair, or another anatomical surface is 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, or more than the active agent(s) deposited on the skin, scalp, or hair of a comparator composition.
- In another aspect, the present application relates to a method of treating and/or preventing a disease, disorder, or condition; or treating and/or preventing symptoms of a disease, disorder, or condition, with one or more active agents comprising:
-
- a) topically applying a rinse-off composition of the present application to a subject in need thereof;
- b) adding water and optionally creating a lather; and
- c) rinsing the composition
wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- In some embodiments, the present application includes a method of treating and/or preventing a disease, disorder, or condition; or treating and/or preventing symptoms of a disease, disorder, or condition, with one or more active agents comprising:
-
- a) topically applying a shampoo composition of the present application to a subject in need thereof;
- b) adding water to create lather; and
- c) rinsing the composition
wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- In another aspect, the present application relates to a method of the body of a subject in need thereof comprising:
-
- a) topically applying a rinse-off composition of the present application to the subject;
- b) adding water and optionally creating lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a method of cleansing hair, scalp, and/or skin of a subject in need thereof comprising:
-
- d) topically applying a rinse-off composition of the present application to the subject;
- e) adding water and optionally creating lather; and
- f) rinsing the composition.
- In some embodiments, the present application includes a method of cleansing hair and scalp of a subject in need thereof comprising:
-
- a) topically applying a shampoo composition of the present application to the subject;
- b) adding water and optionally creating lather; and
- c) rinsing the composition.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application for the administration of one or more active agents to a subject in need thereof. In an embodiment, the present application includes a use of a shampoo composition of the present application for the administration of one or more active agents to a subject in need thereof.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents. In some embodiments, the present application includes a use of a shampoo composition of the present application to treat and/or prevent a disease, disorder, or condition in a subject in need thereof, wherein the disease, disorder, or condition is one that is treatable with the one or more active agents.
- In another aspect, the present application relates to a use of a rinse-off composition of the present application to cleanse the body of a subject in need thereof. In another aspect, the present application relates to a use of a rinse-off composition of the present application to cleanse hair, scalp, and/or skin of a subject in need thereof. In some embodiments, the present application relates to a use of a shampoo composition of the present application to cleanse hair and scalp of a subject in need thereof.
- In some embodiments, the rinse-off composition is used on or applied to the body of the subject. In some embodiments, the rinse-off composition is used on or applied to the skin of the subject. In some embodiments, the rinse-off composition is used on or applied to the hair, scalp, or skin of the subject. In some embodiment, the rinse-off composition is used, or applied to the subject for less than 5 to 15 minutes prior to the optional lathering and the rinsing. In some embodiments, the rinse-off composition is used or applied to the subject for less than 10 minutes prior to the optional lathering and the rinsing. In some embodiments, the rinse-off composition is used or applied to the subject for less than 5 minutes prior to the optional lathering and the rinsing.
- In some embodiments, an effective amount of the rinse-off composition is used or applied, wherein the effective amount is an amount effective to treat a disease, disorder, or condition treatable with the one or more active agents and/or to treat symptoms of a disease, disorder, or condition treatable with the one or more active agents. In some embodiments, the one or more active agents is a corticosteroid and the condition treatable with the active agent is selected from dandruff, seborrheic dermatitis, and/or psoriasis. In some embodiments, the one or more active agents are useful in treating inflammatory skin diseases, inflammatory scalp disease, fungal skin disease, fungal scalp disease, serborrheic dermatitis, psoriasis, dry skin, dry scalp, and/or dandruff.
- For example, the rinse-off compositions may be applied or used at least once a day. However, in another embodiment, the rinse-off compositions are applied or used from about one time per week to 6 times per week. In another embodiment, the rinse-off compositions are applied or used about one time per week to about once or about twice daily. In some embodiments, the rinse-off compositions are applied or used one time per week to one time per two weeks, one time per three weeks, one time per four weeks, or one time per month. In some embodiments, the rinse-off compositions are applied or used one time per day, two times per day, three times per day, or four times per day. The length and timing of the treatments depends on a variety of factors, such as the severity of the disease, disorder or condition, the age of the subject, the concentration and/or the activity of the one or more active agents, and/or a combination thereof. It will also be appreciated that the effective amount of the rinse-off composition used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration is required. For example, the rinse-off compositions may be administered or used in an amount and for duration sufficient to treat the subject.
- In the context of treating a disease, disorder or condition, an effective amount is an amount that, for example, treats the disease, disorder, or condition compared to the treatment without administration or use of the rinse-off compositions of the application. In some embodiments, effective amounts vary according to factors such as the disease state, age, sex, and/or weight of the subject. In a further embodiment, the amount of a given composition that will correspond to an effective amount will vary depending upon factors, such as the given active agent(s), the composition, the type of condition, disease or disorder, the identity of the subject being treated, and the like, but can nevertheless be routinely determined by one skilled in the art.
- In some embodiments, the compositions of the present application are used in the context of, with, or as part of a device. In some embodiments the device is to facilitate use, application, or administration of the composition, for example, but not limited to, a foaming device, an aerosol device, a pump device, a roll-on device, or any other suitable applicator, including brush, comb, sponge, pad, and the like. In some embodiments, the compositions of the present application are used for cosmetic purposes.
- Other features and advantages of the present application will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the application, are given by way of illustration only and the scope of the claims should not be limited by these embodiments, but should be given the broadest interpretation consistent with the description as a whole.
- A replication of the Clobex formula (replicate of Clobex formulation based on U.S. Pat. Nos. 7,316,810, 7,700,081 and 8,066,975) with HBP substituted for clobetasol propionate (CP) was prepared along with a vehicle (HBP replaced by water) to provide benchmarks for subsequent evaluations of prototype rinse-off compositions as shampoo compositions. These contents of these compositions are provided in Table 1.
- The inclusion of 10% ethanol in Clobex shampoo would be expected to have a deleterious effect upon the lathering of a shampoo and may cause irritation if left too long on the skin, but is likely incorporated in the product to help solubilize CP as well as increase the skin absorption of the drug during the 15 minute “leave-on” period instructed in the Clobex product label.
-
TABLE 1 Clobex Replica. API Function Material Wt. Pct. Vehicle Water 71.289 Vehicle/Solvent Ethanol 10.000 Rheology/Coacervate Polyquaternium ™ 10 2.000 Active Agent Halobetasol Propionate 0.050 Primary Sodium Laureth 11.900 Sulfate Co-Surfactant Cocamidopropyl 1.922 Betaine pH Adjustment Citric Acid 0.240 pH Adjustment Sodium Citrate 2.600 Total 100.000 Total Surfactant 13.822 Total Oil Phase 0.050 - The following compositions were prepared using varying surfactant types and levels, varying levels of cationic polymers, and varying types and levels of water-insoluble oil phase solvents.
-
TABLE 2 Exemplary Compositions of the Present Application AA* AA HA HA HA-2 CA CA Wt. Pct. Wt. Pct. Wt. Pct. Wt. Pct. Wt. Pct. Wt. Pct. Wt. Pct. Function Material API Vehicle API Vehicle API API Vehicle Vehicle Water 82 82 79.05 79.05 79.05 79 79 Humectant Glycerin 2 2 2 2 2 2 2 Rheology/Coacervate Polyquaternium 10 2 2 1.55 1.55 1.55 1.6 1.6 API Halobetasol Propionate 0.05 — 0.05 — 0.05 0.05 — Solvent Di Isopropyl Adipate 1.58 1.63 0.75 0.8 0.95 0.75 0.8 Solvent Coconut Oil — — 1 1 1 1 1 Solvent Peppermint Oil — — 0.2 0.2 — 0.2 0.2 Penetration Enhancer Methyl laurate 0.25 0.25 0.25 0.25 0.25 0.25 0.25 Penetration Enhancer Isopropyl Myristate 0.75 0.75 0.75 0.75 0.75 0.75 0.75 Rheology/Gel Phase Cetostearyl Alcohol 0.5 0.5 — — — — — Spreading Agent Cyclomethicone 0.37 0.37 — — — — — Primary Surfactant Sodium Laureth Sulfate 5 5 7 7 7 7 7 Primary Surfactant Sodium Lauryl Sulfate 2 2 2.8 2.8 2.8 2.8 2.8 Co-Surfactant Cocamidopropyl Betaine 2 2 2.8 2.8 2.8 2.8 2.8 Co-Surfactant Cocomonoethanolamide — — 0.3 0.3 0.3 0.3 0.3 Ionic Strength Adj. Sodium Chloride 1 1 1 1 1 1 1 Preservative Symocide PC 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Total 100 100 100 100 100 100 100 Total Surfactant 9 9 12.9 12.9 12.9 12.9 12.9 Total Oil Phase 3.5 3.5 3 3 3 3 3 *AA formulation of Examples 3 and 4 contains 0.2% Peppermint Oil - Compositions HA, HA-2, and CA (shown in Table 2) used a lower total amount of cationic polymer and increased surfactant levels relative to Composition AA (shown in Table 2), but had modifications to the oil phase to improve lathering and rheology. The total oil phase level was reduced and cetostearyl alcohol and cyclomethicone were removed. A higher MW oil component, coconut oil, was introduced for solubility of HBP. The level of di-isopropyl adipate was minimized to that required to solubilize HBP, HA and CA included and peppermint oil to help solubilize HBP.
- (a) Deposition of Active Agent
- The Clobex HBP Replica and Compositions AA, HA, and CA (API) were evaluated for amount of drug deposited in vitro onto human cadaver skin mounted in 15 mm diameter Franz cells maintained at about 35° C. using the following simulated shampooing protocol:
- Product Application
-
- Apply target amount of 17-20 mg per cell, spread if necessary to achieve uniform skin coverage, and leave for 15 min
- Recover any product/drug adhering to spreading device for assay with mobile phase
- Add 200 μL water and mix to create lather for about 30 s
- Dilute with additional 0.5 mL water and mix for 60 sec
- Pour off water/product and retain for assay
- Rinse with 1.0 mL water, recovering for assay
- Termination of test procedures (24 hr)
- Remove receptor fluid and retain for assay
- Remove skin and wipe aggressively with filter paper (soaked in mobile phase) to remove residual product
- Extract filter paper for drug assay
- Cut up skin and extract with mobile phase for drug assay
- Assays:
-
- Adhered drug to spreading device
- Water/product from lathering and dilution
- Rinse water
- Water systems could be combined
- Receptor fluid
- Extract of filter paper used to remove residual product at termination of test
- Extract(s) of skin
- Four replicates of each of the four products were evaluated.
- Table 3 summarizes the amount of HBP detected on the skin surface after 24 hours, which may be considered the amount of drug deposited from the composition during application. All three compositions had considerably higher HBP amounts on after 24 hours than the Clobex Replicate. This suggests that the approach of incorporating HBP in a dispersed oil phase in the shampoo matrix is superior in depositing HBP than the approach used in Clobex of solubilizing the drug in a surfactant matrix containing a relatively high level of ethanol (10%). Composition AA yielded most favorable results.
-
TABLE 3 In Vitro Skin Deposition Results for Compositions AA, CA and HA (API) Compared to Clobex HBP system Clobex Rep. AA CA HA Percent of Applied Amount Cell 1 1.1 28.4 2.1 20.2 Cell 2 2.5 3.4 12.1 0.0 Cell 3 0.6 25.7 14.8 16.0 Cell 4 0.7 26.9 11.3 6.6 Mean 1.2 21.1 10.1 10.7 St Dev 0.9 11.9 5.5 9.1 - (b) Stability
- Tables 4 through 7 provide a summary of the available stability data at three months for Clobex HBP Replica and compositions AA, HA, and CA at 25° C. and 45° C. (accelerated conditions).
- As indicated in Table 4, the Clobex replicate with HBP was clear, and the other final compositions were slightly opaque. The Clobex replicate and formulations HA and CA appeared to be physically stable through three months at 25° C. and 45° C. Composition AA was stable through three months at 45° C. (accelerated conditions).
-
TABLE 4 Stability of Clobex HBP, and Compositions AA, HA and CA (API) Temp. Time (° C.) (month) Clobex Rep. AA HA CA — Initial Solution clear. Blurred Blurred Blurred Free of foreign solution. solution. solution. particles. Free Free Free of foreign of foreign of foreign particles. particles. particles. 25 3 Solution clear. Blurred Blurred Blurred Free of foreign solution. solution. solution. particles. Free Free Free of foreign of foreign of foreign particles. particles. particles. Presence of phase separation. 45 1 Solution clear. Blurred Blurred Blurred Free of foreign solution. solution. solution. particles. Free Free Free of foreign of foreign of foreign particles. particles. particles. 3 Solution clear. Blurred Blurred A little bit Free of foreign solution. solution. blurred particles. Free Free solution. of foreign of foreign Free particles. particles. of foreign particles. - (c) pH Stability:
- All products had relatively stable pH values at 25° C. as shown in Table 5.
-
TABLE 5 pH Stability Data Temp. Time Clobex (° C.) (month) Rep. AA HA CA — Initial 5.91 5.68 5.91 5.80 25 3 5.87 6.65 5.90 5.76 45 3 5.84 5.47 5.54 5.44 - (d) HBP Stability and Impurities
- HBP stability (Table 6) and presence of impurities (Table 7) were assessed for compositions AA, HA and CA (API), along with the Clobex HBP replica at both 25° C. and 45° C.
-
TABLE 6 HBP Stability Data Clobex Temp. Time Rep. AA HA CA (° C.) (month) Percent of Target (0.05% w/w) Initial 100.7 98.9 99.6 98.0 25 3 97.3 98.6 96.9 95.1 45 3 96.2 96.7 96.0 95.3 -
TABLE 7 Total Impurities (%) Data Temp. Time Clobex (° C.) (month) Rep. AA HA CA Initial N/D N/D N/D 0.44 25 3 N/D 1.35 2.03 1.59 45 1 0.52 1.24 1.58 3.50 3 1.00 0.89 0.76 1.38 N/D = Not Detected - The Clobex HBP Replica and compositions AA, HA, and CA (API) formulations were evaluated for in-use properties by seven patients using the following instructions:
-
- “Wet scalp and hair in shower. Dispense about one teaspoon shampoo in palm and apply to scalp, massaging with fingers to assure shampoo is in contact with scalp and not just hair. Continue with showering of rest of body, leaving shampoo in contact with scalp through (and for at least 5 minutes). Add more water to shampoo on scalp and massage to create lather. Rinse, minimizing contact of shampoo with rest of body.”
- The results are shown in Table 8. Based on the compiled rankings, HA was the most preferred followed by CA and both were rated much higher than the Clobex HBP Replica. AA had a similar rating to Clobex HBP Replica.
-
TABLE 8 Wear Study of Compositions AA, HA and CA (API), and Clobex Replica 1. Formulation 2. CA 3. AA 4. HA 5. Clobex 6. Subject #1 7. 2 8. 3 9. 1 10. 4 Rank 11. Subject #1 12. slightly 13. slightly 14. slightly 15. worst Comments pleasant odor, pleasant odor, pleasant odor, odor, good good lather, good foam, densest richest lather, easy good hair feel slightly oily hair lather, easy to rinse, good hair feel rinse, good hair feel feel 16. Subject #2 17. 1 18. 4 19. 3 20. 2 Rank 21. Subject #2 22. slightly 23. very 24. good 25. slightly Comments thin, nice thin, poor viscosity, slight thin, unpleasant fragrance, lather, didn't chemical odor, fragrance, lathered well, feel like cleaned ok lather, rinsed lathered well, rinsed well hair well rinsed well, hair felt clean 26. Subject #3 27. 1 28. 2 29. 3 30. 4 Rank 31. Subject #3 32. better 33. thin, no 34. good 35. pretty Comments viscosity, odor, good viscosity, thin, medicinal unpleasant odor, lather, hair felt peppermint odor, good lather good lather, hair limp but ok fragrance, good but runny, hair felt clean when dry lather, rinsed felt clean and well, hair felt soft bit flat 36. Subject #4 37. 2 38. 4 39. 1 40. 3 Rank 41. Subject #4 42. viscosity 43. runny, 44. clear 45. viscosity Comments ok, cloudy, good slight chemical appearance, ok, smell ok, lather, removed odor, not much very good lather ok, harder cleanly lather, removed viscosity, mild to rinse cleanly scent, ok lather, rinsed cleanly 46. Subject #5 47. 4 48. 3 49. 1 50. 2 Rank 51. Subject #5 52. thinner, 53. decent 54. good 55. good Comments minimal scent, thickness, good thickness, light thickness, better decent lather, lather, easy scent, good lather, easy rinse easy rinse rinse lather, easy rinse 56. Subject #6 57. 2 58. 3 59. 1 60. 4 Rank 61. Subject #6 62. mint with 63. mint 64. best 65. some Comments chemical smell, with chemical appearance and alcohol smell, better viscosity, smell, better texture sticky feel after good removal viscosity, good rinse (like glue) removal 66. Subject #7 67. 3 68. 4 69. 2 70. 1 Rank 71. Subject #7 72. strong 73. strong 74. strong 75. no smell, Comments smell, too smell, ok smell, good ok viscosity, viscous, sticky, viscosity, some viscosity, great great lather, easy no lather, easy lather, easy lather, easy rinse, felt clean rinse, felt clean rinse, felt clean rinse, felt clean 76. Total 77. 15 78. 23 79. 12 80. 20 -
-
TABLE 9 Proposed Composition Trade Name INCI Name Wt. Pct. Function Water Water 68.00 Vehicle Miracare SLB-365 Water, Sodium 25.00 Surfactant (Solvay, Princeton, Trideceth NJ) Sulfate, Sodium Lauroamphoacetate, Cocamide ME Celquat 240C Polyquaternium 10 1.00 Rheology/ (AkzoNobel, Chicago Coacervate IL) Salicylic Acid Salicylic Acid 0.50 Acne Active Castor Oil Ricinus communis 3.50 Water-Immiscible (Castor) Seed Oil Solvent Sodium Chloride Sodium Chloride 1.50 Ionic Strength Adj. Phenoxyethanol Phenoxyethanol 0.50 Preservative - While the present application has been described with reference to examples, it is to be understood that the scope of the claims should not be limited by the embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
- All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.
Claims (30)
1. A rinse-off composition comprising
a) an oil phase; and
b) an aqueous surfactant matrix,
wherein the oil phase comprises one or more active agents dissolved in one or more non-polar, water-immiscible solvents and the oil phase is dispersed in the aqueous surfactant matrix.
2. The rinse-off composition of claim 1 , wherein the aqueous surfactant matrix comprises one or more surfactants and one or more polymers.
3. The rinse-off composition of claim 2 , wherein the one or more surfactants are one or more anionic surfactants and the one or more polymers are one or more cationic polymers.
4. The rinse-off composition of claim 3 , wherein the one or more anionic surfactants and the one or more cationic polymer form coacervates.
5. The rinse-off composition of claim 1 , wherein the aqueous surfactant matrix further comprises water and is substantially free of ethanol and/or other water-miscible solvents.
6. The rinse-off composition of claim 3 , wherein the one or more anionic surfactants are selected from sodium laureth sulfate and sodium lauryl sulfate and mixtures thereof.
7. The rinse-off composition of claim 3 , wherein the one or more cationic polymers are selected from cationic cellulose derivatives, cationic guar derivatives, acrylamidopropyl trimonium chloride copolymer with acrylamide, homopolymers derived from the monomer diallyldimethylammonium chloride, copolymers derived from diallyldimethylammonium chloride and acrylamide, and homopolymers or copolymers of a cationic monomer selected from:
(a) a monomer having the Formula I:
wherein R1 is H or CH3; Y is O or NH; Z is C1-6alkylene; R2, R3, and R4 are each independently C1-22alkyl or C1-22hydroxyalkyl; and X is a monovalent anion selected from halide and C1-4alkyl sulfate; and
(b) diallyldimethylammonium chloride,
(c) and mixtures thereof.
8. The rinse-off composition of claim 7 , wherein the cationic cellulose derivatives are polymeric quaternary ammonium salts derived from the reaction of hydroxyethyl cellulose with a trimethylammonium-substituted epoxide.
9. The rinse-off composition of claim 2 , wherein the one or more surfactants further comprises one or more amphoteric surfactants and/or one or more non-ionic surfactants.
10. The rinse-off composition of claim 9 , wherein the one or more amphoteric surfactants are selected from amphocarboxylates, alkyl betaines, amidoalkylbetaines, amidoalkylsultaines, amphophosphates , phosphobetaines , pyrophosphobetaines, c arboxy alkyl alkyl polyamines, cocoamidopropyl betaine, and mixtures thereof.
11. The rinse-off composition of claim 9 , wherein the one or more non-ionic surfactants are selected from polysorbate 20, C8-22alkyl glucosides, coconut fatty acid monoethanolamides, coconut fatty acid diethanolamides, cocomonoethanolamide, and mixtures thereof.
12. The rinse-off composition of claim 1 , wherein the one or more non-polar, water-immiscible solvents are selected from di-isopropyl adipate, peppermint oil, coconut oil, and mixtures thereof.
13. The rinse-off composition of claim 12 , wherein the oil phase further comprises one or more water-immiscible or water-insoluble components selected from dimethicone, cyclomethicone, fatty alcohols, and mixtures thereof.
14. The rinse-off composition of claim 1 , wherein the one or more active agents are selected from adrenergic agent, adrenocortical steroid, adrenocortical suppressant, aldosterone antagonist, amino acid, anabolic, analeptic, analgesic, anesthetic, anorectic, anti-acne agent, anti-adrenergic, anti-allergic, anti-amebic, anti-anemic, anti-anginal, anti-arthritic, anti-asthmatic, anti-atherosclerotic, antibacterial, anticholinergic, anticoagulant, anticonvulsant, antidepressant, antidiabetic, antidiarrheal, antidiuretic, anti-emetic, anti-epileptic, antifibrinolytic, antifungal, antihemorrhagic, antihistamine, antihyperlipidemia, antihypertensive, antihypotensive, anti-infective, anti-inflammatory, antimicrobial, antimigraine, antimitotic, antimycotic, antinauseant, antineoplastic, antineutropenic, antiparasitic, antiproliferative, antipsychotic, antirheumatic, antiseborrheic, antisecretory, antispasmodic, antithrombotic, antiulcerative, antiviral, appetite suppressant, blood glucose regulator, bone resorption inhibitor, bronchodilator, cardiovascular agent, cholinergic, depressant, diagnostic aid, diuretic, dopaminergic agent, estrogen receptor agonist, fibrinolytic, fluorescent agent, free oxygen radical scavenger, gastric acid suppressant, gastrointestinal motility effector, glucocorticoid, hair growth stimulant, hemostatic, histamine H2 receptor antagonists, hormone, hypocholesterolemic, hypoglycemic, hypolipidemic, hypotensive, imaging agent, immunizing agent, immunomodulator, immunoregulator, immunostimulant, immunosuppressant, keratolytic, LHRH agonist, mood regulator, mucolytic, mydriatic, nasal decongestant, neuromuscular blocking agent, neuroprotective, NMDA antagonist, non-hormonal sterol derivative, plasminogen activator, platelet activating factor antagonist, platelet aggregation inhibitor, psychotropic, radioactive agent, scabicide, sclerosing agent, sedative, sedative-hypnotic, selective adenosine Al antagonist, serotonin antagonist, serotonin inhibitor, serotonin receptor antagonist, steroid, thyroid hormone, thyroid inhibitor, thyromimetic, tranquilizer, amyotrophic lateral sclerosis agent, cerebral ischemia agent, Paget's disease agent, unstable angina agent, vasoconstrictor, vasodilator, wound healing agent, xanthine oxidase inhibitor, growth-promoting agent, hair-strengthening agent, coloring agent, sunblocking agent, hair removal/depilatory agent, anti-perspirant agent, pediculosides, pesticides, retinoids, vitamins, liphophilic vitamins, vitamin derivatives, cannabinoids, corticosteroids, and combinations thereof.
15. The rinse-off composition of claim 14 , wherein the active agent is halobetasol propionate.
16. The rinse-off composition of claim 1 , wherein the one or more active agents are selected from hydrocortisone, alclometasone, amelometasone, beclometasone, betamethasone, cormetasone, desoximetasone, dexamethasone, flumetasone, halometasone, icometasone, mometasone, paramethasone, amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, fluocortolone, alclometasone dipropionate, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clobetasone butyrate, fluprednidene acetate, mometasone furoate, ciclesonide, cortisone acetate, halobestasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone valerate, prednicarbate, clocortolone pivolate, tixocortol pivalate, progesterone, azole, ketoconazole, econazole, luluconazole, selenium sulfide, pyrithione zinc, terbinafine, sodium sulfacetamide, isotretinoin, tretinoic acid, tar, piroctone olamine, coal tar, sulfur, climbazole, ciclopirox olamine, zinc omadine, salicylic acid, azelaic acid, tranexamic acid, cannabidiol (CBD), tetrahydrocannabiol (THC), vitamin D, vitamin D analogs, calcipotriene, calcipotriol, vitamin A, retinol, resorcinol, lidocaine, minoxidil and mixtures thereof.
17. The rinse-off composition of claim 1 , wherein about 25% to about 50% or about 27% to about 45% of the one or more active agents are solubilized in the one or more non-polar water-immiscible solvents.
18. The rinse-off composition of claim 1 , wherein the rinse-off composition provides a deposition of the one or more active agents onto an applied surface that is about 5% to about 30% of the total amount of the one or more active agents in the composition, wherein the composition is applied to the surface for less than 15 minutes followed by rinsing.
19. The rinse-off composition of claim 1 , wherein the rinse-off composition provides a deposition of the one or more active agents onto the applied surface that is at least 2.1%, 3.4%, or 6.6% or more than 0.6%, 0.7%, 1.1% or 2.5% of the total amount of the one or more active agents in the composition.
20. The rinse-off composition of claim 1 , wherein the composition is a facial, hand, or body cleanser or wash, a bath or shower product, or a shampoo composition and/or hair conditioning composition.
21. A method of topically administering one or more active agents to a subject in need thereof comprising:
a) topically applying a rinse-off composition of claim 1 to the subject;
b) adding water and optionally creating a lather; and
c) rinsing the composition.
22. The method of claim 21 , wherein steps a) and b) are separated by less than about 15 minutes, less than about 10 minutes, or less than about 5 minutes.
23. The method of claim 21 , wherein the rinse-off composition is applied to the skin, the hair, scalp, and or another anatomical surface of the subject.
24. The method of claim 21 , wherein an effective amount of the rinse-off composition is applied, wherein the effective amount is an amount effective to treat a disease, disorder, or condition treatable with the one or more active agents and/or to treat symptoms of a disease, disorder, or condition treatable with the one or more active agents.
25. The method of claim 24 , wherein the active agent is applied for treatment of a disease, disorder, or condition treatable with the one or more active agents is inflammatory skin diseases, inflammatory scalp disease, fungal skin disease, fungal scalp disease, serborrheic dermatitis, psoriasis, acne, anti-aging, anti-wrinkle, skin lightening, hyperpigmentation, pain relief, skin rejuvenation, dry skin, dry scalp, and/or dandruff.
26. The method of claim 21 , wherein the rinse-off composition is applied to the subject for less than 5 minutes to 15 minutes prior to the rinsing.
27. The method of claim 21 , wherein the amount of one or more active agents deposited on the skin, the hair, scalp and/or other anatomical surface of the subject step is at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% of the total concentration of the active agents(s) in the composition, wherein the composition is applied to the skin, the hair, scalp and/or other anatomical surface for less than 15 minutes followed by rinsing.
28. The method of claim 21 , wherein the rinse-off composition is a facial, hand, or body cleanser or wash, a bath or shower product, or a shampoo composition and/or hair conditioning composition.
29. A method of treating and/or preventing a disease, disorder, or condition, or treating and/or preventing symptoms of a disorder, disease, or condition, with one or more active agents comprising:
a) topically applying the rinse-off composition of claim 1 to a subject in need thereof;
b) adding water and optionally creating a lather; and
c) rinsing the composition,
wherein the disease, disorder or condition is one that is treatable with the one or more active agents.
30. A method of topically administering a rinse-off composition comprising halobetasol propionate to a subject in need thereof, comprising:
a) topically applying a rinse-off composition comprising halobetasol propionate to the subject;
b) adding water and optionally creating a lather; and
c) rinsing the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/365,074 US20230381102A1 (en) | 2019-03-14 | 2023-08-03 | Rinse-off compositions and uses thereof for delivery of active agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962818366P | 2019-03-14 | 2019-03-14 | |
US16/820,128 US10945952B2 (en) | 2019-03-14 | 2020-03-16 | Rinse-off compositions and uses thereof for delivery of active agents |
US17/168,998 US20210169800A1 (en) | 2019-03-14 | 2021-02-05 | Rinse-off compositions and uses thereof for delivery of active agents |
US18/365,074 US20230381102A1 (en) | 2019-03-14 | 2023-08-03 | Rinse-off compositions and uses thereof for delivery of active agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/168,998 Continuation US20210169800A1 (en) | 2019-03-14 | 2021-02-05 | Rinse-off compositions and uses thereof for delivery of active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230381102A1 true US20230381102A1 (en) | 2023-11-30 |
Family
ID=72424424
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/820,128 Active US10945952B2 (en) | 2019-03-14 | 2020-03-16 | Rinse-off compositions and uses thereof for delivery of active agents |
US17/168,998 Abandoned US20210169800A1 (en) | 2019-03-14 | 2021-02-05 | Rinse-off compositions and uses thereof for delivery of active agents |
US18/365,074 Pending US20230381102A1 (en) | 2019-03-14 | 2023-08-03 | Rinse-off compositions and uses thereof for delivery of active agents |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/820,128 Active US10945952B2 (en) | 2019-03-14 | 2020-03-16 | Rinse-off compositions and uses thereof for delivery of active agents |
US17/168,998 Abandoned US20210169800A1 (en) | 2019-03-14 | 2021-02-05 | Rinse-off compositions and uses thereof for delivery of active agents |
Country Status (5)
Country | Link |
---|---|
US (3) | US10945952B2 (en) |
EP (1) | EP3937905A4 (en) |
JP (1) | JP2022525221A (en) |
CA (1) | CA3133174A1 (en) |
WO (1) | WO2020181395A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3937905A4 (en) * | 2019-03-14 | 2022-12-28 | Crescita Therapeutics Inc. | Rinse-off compositions and uses thereof for delivery of active agents |
US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
US11524040B2 (en) | 2020-08-24 | 2022-12-13 | Charlotte's Web, Inc. | Composition for the treatment of acne |
US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4835148A (en) | 1986-02-24 | 1989-05-30 | The Procter & Gamble Co. | Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents |
GB9313866D0 (en) | 1993-07-05 | 1993-08-18 | Diomed Dev Ltd | Compositions for the treatment of inflammatory proliferative skin disease and their use |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
US6183757B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing |
FR2761600B1 (en) * | 1998-06-19 | 2000-03-31 | Oreal | FOAMING COMPOSITION FOR THE WASHING AND TREATMENT OF HAIR AND / OR SCALP BASED ON AN ACTIVE INGREDIENT, AN ANIONIC SURFACTANT, AN AMPHOTERIC SURFACTANT AND A PROPENETANT |
US6495498B2 (en) | 1999-05-27 | 2002-12-17 | Johnson & Johnson Consumer Companies, Inc. | Detergent compositions with enhanced depositing, conditioning and softness capabilities |
US20030133899A1 (en) | 2000-10-31 | 2003-07-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Personal cleansing compositions that contain surfactants, co-surfactants, water insoluble solids and/or liquids and cationic conditioning polymers |
US6991781B2 (en) | 2001-01-17 | 2006-01-31 | The Procter & Gamble Company | Delivery of reactive agents via bi-layer structures for use in shelf-stable products |
CA2459648A1 (en) | 2001-10-18 | 2003-04-24 | The Procter & Gamble Company | Shampoo compositions with anionic surfactants, amphoteric surfactants and cationic polymers |
US20030161802A1 (en) * | 2002-02-05 | 2003-08-28 | Flammer Linda J. | Anti-dandruff and anti-itch compositions containing sensate and sensate enhancer-containing compounds |
US8349301B2 (en) * | 2002-06-04 | 2013-01-08 | The Procter & Gamble Company | Shampoo containing a gel network |
US20060057075A1 (en) * | 2004-08-02 | 2006-03-16 | Moshe Arkin | Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof |
US9314431B2 (en) | 2005-02-14 | 2016-04-19 | Transdermal Corp | Solubilized benzoyl small molecule |
EP3141246A1 (en) | 2009-08-31 | 2017-03-15 | Dr. Reddy's Laboratories Ltd. | Topical formulations comprising a steroid |
US8809307B2 (en) | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
EP3295931A1 (en) | 2011-10-07 | 2018-03-21 | The Procter & Gamble Company | Shampoo composition containing a gel network |
US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
CN106794126A (en) | 2014-08-27 | 2017-05-31 | 艾伯维公司 | Local preparation |
WO2016094617A1 (en) | 2014-12-11 | 2016-06-16 | Phosphorex, Inc. | Aqueous topical drug formulation with controlled release and increased stability |
US20160361264A1 (en) | 2015-06-12 | 2016-12-15 | Salvona Llc | Delivery of pharmaceutical active ingredients through the skin and hair follicles into dermis and transdermal delivery |
SI3310389T1 (en) | 2015-06-18 | 2020-11-30 | Bausch Health Ireland Limited | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
WO2018005453A1 (en) | 2016-06-27 | 2018-01-04 | The Procter & Gamble Company | Shampoo composition containing a gel network |
MX2019004576A (en) | 2016-10-21 | 2019-09-16 | Crescita Therapeutics Inc | Pharmaceutical compositions. |
WO2019135123A1 (en) | 2018-01-02 | 2019-07-11 | Nal Pharmaceutical Group Limited | Liquid dosage form for topical application |
US20190224112A1 (en) | 2018-01-25 | 2019-07-25 | Lupin Atlantis Holdings Sa | Methods and Kit for Treating Skin Disorders |
WO2020064843A1 (en) | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses |
EP3937905A4 (en) * | 2019-03-14 | 2022-12-28 | Crescita Therapeutics Inc. | Rinse-off compositions and uses thereof for delivery of active agents |
-
2020
- 2020-03-16 EP EP20770817.3A patent/EP3937905A4/en not_active Withdrawn
- 2020-03-16 US US16/820,128 patent/US10945952B2/en active Active
- 2020-03-16 JP JP2021555588A patent/JP2022525221A/en active Pending
- 2020-03-16 WO PCT/CA2020/050350 patent/WO2020181395A1/en unknown
- 2020-03-16 CA CA3133174A patent/CA3133174A1/en active Pending
-
2021
- 2021-02-05 US US17/168,998 patent/US20210169800A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/365,074 patent/US20230381102A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200289415A1 (en) | 2020-09-17 |
EP3937905A1 (en) | 2022-01-19 |
EP3937905A4 (en) | 2022-12-28 |
WO2020181395A1 (en) | 2020-09-17 |
US20210169800A1 (en) | 2021-06-10 |
CA3133174A1 (en) | 2020-09-17 |
JP2022525221A (en) | 2022-05-11 |
US10945952B2 (en) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10945952B2 (en) | Rinse-off compositions and uses thereof for delivery of active agents | |
TWI274588B (en) | Novel topical formulations | |
US20020077256A1 (en) | Novel detergent compositions with enhanced depositing, conditioning and softness capabilities | |
JPH08509224A (en) | How to use hesperetin to control sebum and to treat acne | |
CN103561724A (en) | Pharmaceutical composition for administration to nails | |
US9504661B2 (en) | Dapsone to treat rosacea | |
JP2013538853A (en) | Treatment with combined use of acne | |
JP5604792B2 (en) | Pharmaceutical composition for external use | |
JP2005524651A (en) | Topical dapsone for the treatment of acne | |
JP2920611B2 (en) | Topical treatment for dermatitis | |
JPH1192378A (en) | Hair tonic liquid for external use | |
JP5989271B1 (en) | Scalp composition for external use | |
JP2000327516A (en) | Gel-like composition for external application to skin | |
JP2005008596A (en) | Ophthalmological composition | |
JP3470131B2 (en) | Long-acting nasal drops | |
JP3193617B2 (en) | Refreshing agent and composition for human body | |
JP7312527B2 (en) | emulsion composition | |
EP4021456A1 (en) | Treatment of skin conditions using high krafft temperature anionic surfactants | |
JP2023018775A (en) | external composition | |
US20230310429A1 (en) | Formulations for reducing hair loss and/or increasing hair regrowth | |
EP4173612A1 (en) | Compositions suitable for use in skin care | |
JP2002265363A (en) | Skin care preparation for improving stress microcirculation disorder | |
JPH10251293A (en) | Dermal collagen fascicular normalizing agent | |
JPH06329520A (en) | Hair growth quickening agent | |
MXPA98010222A (en) | Nasal atomizer containing an intranasal steroid and an antihistam |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CRESCITA THERAPEUTICS, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KELM, GARY ROBERT;HULL, WADE;MURPHY, CAROLYN SHAWN;SIGNING DATES FROM 20190326 TO 20190327;REEL/FRAME:064645/0112 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |